

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT


(10) International Publication Number
WO 2004/031142 A2

- (51) International Patent Classification⁷: **C07D**
- (21) International Application Number:
PCT/US2003/028782
- (22) International Filing Date:
12 September 2003 (12.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/411,118 16 September 2002 (16.09.2002) US
- (71) Applicant (for all designated States except US): TEXAS
TECH UNIVERSITY SYSTEM [US/US]; Lubbock, TX
79409-2007 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SHAW, Robert, W.

- [US/US]; 3505 93rd Street, Lubbock, TX 79423 (US).
KIM, Sung-Kun [KR/US]; 1001 N. Indiana Avenue,
#4703, Lubbock, TX 79415 (US).
- (74) Agents: **CHWANG, T., Ling** et al.; Jackson Walker L.L.P.,
Suite 600, 2435 N. Central Expressway, Richardson, TX
75080 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: INHIBITION OF METALLO-BETA-LACTAMASE



(57) Abstract: A method to identify a high affinity nucleic acid ligand to inhibit the activity of a lactamase enzyme. The method comprises several steps that initially involve preparing a candidate mixture of nucleic acids. The candidate mixture of nucleic acids is then allowed to make contact with the lactamase enzyme under controlled conditions of temperature, ionic strength and pH; the combination forms a candidate-enzyme mixture. The target nucleic acids are partitioned from the remainder of the candidate mixture. The target nucleic acids that have been partitioned are amplified to yield a pool of nucleic acids enriched with target nucleic acid sequences. The enriched pool of target nucleic acids have a relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase are identified. Nucleic acid ligands that inhibit an activity of lactamase. The lactamase includes class B, metallo- β -lactamase.

BEST AVAILABLE COPY

WO 2004/031142 A2



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished
upon receipt of that report*

INHIBITION OF METALLO-BETA-LACTAMASE

INHIBITION OF METALLO-BETA-LACTAMASE

INTRODUCTION

[0001] One aspect of the current invention is a method for identifying a high affinity nucleic acid ligand to inhibit the activity of a lactamase enzyme. The method comprises several steps that initially involve preparing a candidate mixture of nucleic acids. The candidate mixture of nucleic acids is then allowed to make contact with the lactamase enzyme under controlled conditions of temperature, ionic strength and pH; the combination forms a candidate-enzyme mixture. Not all candidates bind tightly to the enzyme. The target nucleic acids may be easily partitioned from the remainder of the candidate mixture. Partitioning the target-nucleic acids from the remainder of the candidate mixture can be performed by many methods known to one skilled in the art. Once the target nucleic acids have been partitioned, they can be amplified to yield a pool of nucleic acids enriched with target nucleic acid sequences. The enriched pool of target nucleic acids have a relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase may be identified through methods known to one skilled in the art of molecular biology (e.g. DNA sequencing).

[0002] Another aspect of the current invention involves nucleic acid ligands that inhibit an activity of lactamase. In a preferred embodiment, the lactamase is a class B, metallo- β -lactamase. Another preferred embodiment includes specific nucleic acid ligands that inhibit *B. cereus* 5/B/6 metallo- β -lactamase. Yet another preferred embodiment includes specific nucleic acid ligands that inhibit *B. cereus* 569/H/9 metallo- β -lactamase.

[0003] **β -lactam antibiotics:** The β -lactam antibiotics are analogs of a peptidoglycan that is involved in bacterial cell wall synthesis. Common examples of β -lactam antibiotics are penicillins, cephalosporins, monobactams and carbapenems. The targets of the β -lactam antibiotics are D-alanyl-D-alanine carboxypeptidases/transpeptidases ("DD-peptidases") that catalyze the formation of the peptide cross-links of the peptidoglycan in the final stages of the bacterial cell wall synthesis. The β -lactam antibiotics inhibit DD-peptidases by forming a stable covalent acyl-enzyme complex with the enzyme that has a longer half-life than that formed with the peptidoglycan, thus disrupting the construction of the bacterial cell

wall, thereby causing the death of bacteria (Kelly et al., 1988; Ghuysen, 1988). Antibacterial agents typically have easy access to the external surface of the cytoplasmic membrane, which is the site where bacterial cell wall synthesis occurs. Since the mammalian cells have a different membrane with no cell wall structures, the β -lactams are highly specific for bacteria and have few side effects even at high concentrations of β -lactam antibiotics (Maugh, 1981).

[0004] The general structures of penicillins and cephalosporins are shown in Figure 2, and Figure 3 shows the comparison of the structure of penicillins with the structure of D-alanyl-D-alanine-peptidoglycan (Suskoviae et al., 1991). When the β -lactam antibiotic compounds are held in a strained configuration by the ring system, the β -lactam and the adjacent atoms have a spatial configuration similar to that of peptidoglycan. Although not wanting to be bound by theory, it is this similarity that gives the antibiotics their bactericidal effects. Unfortunately, some bacteria have become resistant to such antibiotics. One defense that antibiotic resistant bacterium have acquired is an enzyme called β -lactamase (β -lactamhydrolyase, EC 3.5.2.6). β -lactamases are highly efficient enzymes that catalyze the hydrolysis of the β -lactam rings of antibiotics (e.g. penicillins, cephalosporins, monobactams and carbapenems) causing these compounds to quickly lose their bactericidal activity (Fisher et al., 1981; Maugh, 1981). The catalysis of hydrolysis of a generic β -lactam ring by a β -lactamases (Livermore, 1991) is shown in Figure 1.

[0005] Bacteria that have acquired the genes for the production of β -lactamases are resistant to β -lactam antibiotics (Neu, 1992), and past research ideology on developing new β -lactam antibiotics has focused upon keeping ahead of the spread of the bacterial drug-resistance by making slight alterations in the structures of the existing β -lactam antibiotics. For example, cephalosporins have passed through four generations (Maugh, 1981; Pitout et al., 1997). But there are limits on utilizing chemical manipulation of the existing groups of antibiotics. Therefore, it is increasingly important to design new types of antibiotics and mechanism-based β -lactamase inhibitors, and to understand the mechanisms by which β -lactamases function. Although the use of β -lactam/ β -lactamase inhibitor combinations has increased, the design of a therapeutically useful β -lactam antibiotics or inhibitors requires a more detailed understanding of the function of β -lactamases. Studies of the chemical

reaction mechanisms of β -lactamases are of vital importance in designing new antibiotic compounds and new β -lactamase inhibitors (Abraham and Waley, 1979; Brenner and Knowles, 1984).

[0006] **Classification of β -lactamases.** Bacteria produce a wide range of β -lactamases. An incomplete list of bacteria that produce β -lactamases include *Bacillus anthracis*, *Bacillus cereus*, *Bacillus fragilis*, *Escherichia coli*, *Aeromonas hydrophila*, *Bacteroides*, *Staphylococcus epidermidis*, *Streptococcus*, *Pseudomonas aeruginosa*, *Providencia*, *Haemophilus*, *Xanthomonas maltophilia*, *Acinetobacter*, *Citrobacter*, *Enterobacter* and *Branhamella* (Danziger and Pendland, 1995). β -lactamases are classified on the basis of their primary structures and catalytic properties. There are currently four classes of β -lactamases: class A, B, C and D (Ambler, 1980; Ambler et al., 1991; Joris et al., 1991; Frere, 1995). Class A, C and D β -lactamases are serine-active-site enzymes that resemble serine proteases and form an acyl-enzyme intermediate with an active-site serine during the catalysis of β -lactam antibiotics (Rahil and Pratt, 1991). Class A β -lactamases are soluble enzymes, and the class C β -lactamases are very similar to class A β -lactamases except they are membrane bound (Hussain et al., 1987). Class D β -lactamases do not exhibit primary sequence similarities to class A and C β -lactamases (Joris et al., 1991; Ledent et al., 1993). The class B β -lactamases, on the other hand, is quite different from the other classes of β -lactamases. These are metallo- β -lactamases, which require divalent metal ions for enzymatic activity (Ambler, 1980; Abraham and Waley, 1979). Native class B β -lactamases are isolated with one or two zinc ions bound to their active sites (Carfi et al., 1995; Concha et al., 1996).

[0007] The β -lactam antibiotics that are substrates of class B β -lactamases include penicillin derivatives and cephalosporin derivatives. (Felici et al., 1997; Felici and Amicosante, 1995; Felici et al., 1993). *B. cereus* 569/H/9 β -lactamase I is 8,800 times less active with cephalosporin C than the metallo- β -lactamase (Abraham and Waley, 1979). Hydrolysis of β -lactam antibiotics such as carbapenems, cephamycins and imipenem, which are normally resistant to the serine β -lactamase, is also catalyzed by the class B β -lactamases (Felici et al., 1993; Felici and Amicosante, 1995; Rasmussen et al., 1994). The inhibitors for

other classes of β -lactamases such as penem, 6- β -iodopenicillanic acid, penicillanic acid sulfone and clavulanic acid do not inhibit class B β -lactamases (Felici and Amicosante, 1995; Matagne et al., 1995). Recently a series of mercaptoacetic acid thiol esters (Payne et al., 1997; Yang and Crowder, 1999) and thiomandelic acid (Mollard et al., 2001) have been identified as metallo- β -lactamase inhibitors. Also, understanding the structure and dynamics of metallo- β -lactamases has been studied (Carfi et al., 1995; Concha et al., 1996; Scrofani et al., 1999; Concha et al., 2000). However, there is still a need to develop more effective inhibitors for metallo- β -lactamases.

[0008] Metallo- β -lactamases have been detected in an increasing number of pathogenic bacteria including *Anthraxis*, *Bacillus*, *Bacteroides*, *Xanthomonas*, *Aeromonas*, *Pseudomonas*, *Stenotrophomonas*, *Klebsiella*, *Flavobacterium*, *Legionella*, *Enterobacter* and *Serratia* (Felici and Amicosante, 1995; Payne, 1993; Payne et al., 1997). These findings underline the spreading of metallo- β -lactamases genes among pathogenic bacteria.

[0009] Metallo- β -lactamases from *B. cereus* 5/B/6. The first metallo- β -lactamase was identified in *B. cereus* 569 (Sabath and Abraham, 1966). It was shown that a part of the cephalosporinase activity in the crude penicillinase preparation from *B. cereus* strain 569 required Zn^{2+} for maximum activity. This enzyme was reported to have unique thermal stability. Heating at 60°C for 30 min. does not abolish the catalytic activity of this enzyme (Crompton et al., 1962; Davies et al., 1974). The first purified metallo- β -lactamases were reported to have been obtained by Kuwabara et al. (1970). From *B. cereus* 569/H, a spontaneous mutant of strain 569 produces class B β -lactamases constitutively (Kogut et al., 1956). The purification procedure was performed by Kuwabara and Lloyd (1971).

[0010] Another *B. cereus* strain (5/B) was found to produce one class A β -lactamase and one metallo- β -lactamase. This metallo- β -lactamase is very similar to the metallo- β -lactamases produced by *B. cereus* 569 and 569/H except with slightly different substrate specificity (Crompton et al., 1962). *B. cereus* 5/B/6, a mutant form of *B. cereus* 5/B, produces only the metallo- β -lactamase due to a mutation in the structural gene required for the synthesis of the class A β -lactamases (Davies et al., 1975; Abraham and Waley, 1979). The metallo- β -lactamases from *B. cereus* strain 5/B/6 was later purified in a similar manner as

B. cereus 569/H/9 (Thatcher, 1975). The metallo- β -lactamases from these strains of *B. cereus*, which are isolated with one or two Zn^{2+} ions at the active site, were among the first to be studied of the class B enzymes (Ambler, 1985; Bicknell et al., 1986; Sutton et al., 1987; Meyers and Shaw, 1989). The metallo- β -lactamases from these strains of *B. cereus* are very similar. They both consist of 227 amino acid residues among which 209 residues are identical (Lim et al., 1988). Although these β -lactamases are isolated with a Zn^{2+} bound at the active site, other metal ions including Co^{2+} , Cd^{2+} , Mn^{2+} , Hg^{2+} and Cu^{2+} support some catalytic activity of the enzymes (Davies and Abraham, 1974; Hilliard and Shaw, 1992; Hilliard, 1995).

[0011] The metallo- β -lactamases from *B. cereus* 569/H/9 and 5/B/6 are secreted extracellularly. The latter enzyme has a 29 amino acid leader sequence before it is secreted from the cell. The gene for this enzyme has been cloned, sequenced and characterized in great detail in *E. coli*. It has also been expressed as an intracellular enzyme with the signal sequence at relatively low levels in *E. coli* (Lim et al., 1988). It was also revealed that the metallo- β -lactamases from *B. cereus* strains 5/B/6 and 569/H/9 differ by only 18 amino acid residues (Lim et al., 1988). Even though the procedure for production and purification of this enzyme from *B. cereus* 5/B/6 cultures was greatly improved (Meyers and Shaw, 1989), hyperexpression in *E. coli* was still desirable. The construct used at that time did not achieve this goal (Lim et al., 1988). The main cause of the low levels of expression was postulated to be the presence of the 29 amino acid leader peptide at the 5' end of this β -lactamase which signals the secretion of the enzyme from the *B. cereus* cell (Shaw et al., 1991).

[0012] Site-directed mutagenesis was performed to remove the leader sequence and introduce a NdeI restriction endonuclease site (Shaw et al., 1991) at the initiator codon of the *B. cereus* 5/B/6 β -lactamase structural gene as a fragment between a NdeI and a SacI site. This construct allowed the cloning of just the *B. cereus* 5/B/6 β -lactamase structural gene sequence into the *E. coli* expression vector pRE2 (Reddy et al., 1989). This recombinant plasmid pRE2 was chosen because a gene cloned into the unique NdeI and SacI restriction endonuclease sites within its polylinker region is correctly oriented and under the control of its strong P_L promoter. The resulting plasmid is denoted as pRE2/*bla*. In the *E. coli* MZ-1, the temperature sensitive cI repressor binds to the P_L promoter and prevents the expression of the *B. cereus* 5/B/6 β -lactamase gene on plasmid pRE2/*bla* at low temperatures. The cI

protein is denatured at higher temperatures allowing the expression of *B. cereus* 5/B/6 β -lactamases at high levels (Nagai and Thogersen, 1984; Zuber et al., 1987). Subsequent purification of wild type and mutant *B. cereus* 5/B/6 β -lactamases resulted in a high yield of the metallo- β -lactamase that is identical to that purified from *B. cereus* 5/B/6 (Myers and Shaw, 1989; Shaw et al., 1991).

[0013] The invention described herein has utilized the method of Systematic Evolution of Ligands by Exponential Enrichment ("SELEX") to develop nucleic acid ligands for a lactamase enzyme. The nucleic acid ligands can be utilized as metallo- β -lactamase inhibitors.

DESCRIPTION OF FIGURES

[0014] Figure 1 shows the catalysis of hydrolysis of a generic β -lactam by a β -lactamases;

[0015] Figure 2 shows the general structures of penicillins and cephalosporins;

[0016] Figure 3 shows the comparison of the structure of penicillins with the structure of D-alanyl-D-alanine-peptidoglycan;

[0017] Figure 4 shows a diagrammatic representation of the SELEX procedure that was modified from Gold et al., 1995;

[0018] Figure 5 shows a determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by EDTA. The enzyme was preincubated with/without EDTA in the buffer (50 mM MOPS, pH = 7.0) for 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0019] Figure 6 shows a Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by EDTA. Open square: $[I] = 0 \mu\text{M}$; open circle: $[I] = 3 \mu\text{M}$; filled square: $[I] = 4 \mu\text{M}$; filled diamond: $[I] = 5 \mu\text{M}$. $I = \text{EDTA}$.

[0020] Figure 7 shows a slope replot to estimate K_i for EDTA. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 6 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0021] Figure 8 shows a intercept replot to estimate K_i' for EDTA. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 6 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity

Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0022] Figure 9 shows a determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by 2-mercaptoethanol. The enzyme was preincubated with/without 2-mercaptoethanol in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0023] Figure 10 shows a Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by 2-mercaptoethanol. Open square: $[I] = 0 \mu M$; filled square: $[I] = 3 \mu M$; open circle: $[I] = 4 \mu M$; filled diamond: $[I] = 5 \mu M$; open triangle: $[I] = 6 \mu M$. $I = 2$ -mercaptoethanol.

[0024] Figure 11 shows a slope replot to estimate K_i for 2-mercaptoethanol. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 10 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0025] Figure 12 shows a intercept replot to estimate K_i' for 2-mercaptoethanol. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 10 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0026] Figure 13 shows the existence of a nucleic acid:protein complex. On the left, the gel was stained by ethidium bromide. On the right, the gel was stained with Coomassie Brilliant Blue R250. The bound ssDNA can be recognized by ethidium bromide fluorescence and the protein can be identified by Coomassie Brilliant Blue R250. In this experiment, 20 μM enzyme and 1.5 μM ssDNA were used to make the complex. The buffer used for incubation was 20 mM TA (20 mM Tris/20 mM acetate) (pH = 7.0) and 1 mM $ZnSO_4$. The *B. cereus* 5/B/6 metallo- β -lactamase is a cationic enzyme. If there were no ssDNA binding to the enzyme, the enzyme would not migrate into the gel but would rather

travel up the gel toward the cathode and out of the sample well area. The bound ssDNA provides negative charges for migration down the gel toward the anode.

[0027] In Figure 14 shows PCR products from SELEX migrated differently compared from the initial random ssDNA. This difference of migration and the broad nature of band of the PCR products can be due to the variety of possible secondary and tertiary structures of the PCR products.

[0028] Figure 14 shows a comparison of the initial random ssDNA with the ssDNA after SELEX on a native gel. The first lane contained initial random ssDNA. The second lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The fourth, fifth, sixth and seventh lanes contained PCR products after the eight round of SELEX. A 12% (w/v) polyacrylamide gel (29:1 mono:bis) was used in TA buffer.

[0029] Figure 15 shows a comparison of the initial random ssDNA with the ssDNA after SELEX on a denaturing gel. The left lane contained ssDNA after SELEX and the right lane contained initial random ssDNA. The 12% polyacrylamide gel (29:1 mono:bis) was run with 8M urea in TBE buffer (45 mM Tris, 45 mM boric acid and 1 mM EDTA, pH = 8.0).

[0030] Figure 16 shows the early rounds of SELEX. The first, second, third lanes are for the first, third, fifth rounds of SELEX, respectively. The gel shift assays were carried out as described in Methods. The first round contained 20 μ M enzyme, 3 μ M ssDNA and 10 mM NaCl. The third round contained 20 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The fifth round contained 10 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl.

[0031] Figure 17 shows a PCR of ssDNA from the first round of SELEX. The condition of the PCR was described in Methods. The first lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The band excised was chosen because its migration on an 8 M urea gel matched the migration of the initial random ssDNA.

[0032] Figure 18 shows the middle rounds of SELEX. The first, second, third lanes are for the sixth, seventh, eighth round SELEX, respectively. The gel shift assays were carried out as described in Methods. The sixth round contained 5 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The seventh round contained 5 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The eighth round contained 2 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl.

[0033] Figure 19 shows a PCR of ssDNA from the ninth round of SELEX. The condition of the PCR was described in Methods. The first lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The band excised was chosen because its migration on the 8 M urea gel matched the migration of the initial random ssDNA.

[0034] Figure 20 shows the late rounds of SELEX. The first, second, third, fourth, fifth, sixth and seventh lanes are for the ninth, twelfth, thirteenth, fifteenth, sixteenth, seventeenth, and twenty-first round SELEX, respectively. The gel shift assays were carried out as described in Methods. The ninth and twelfth round contained 1.5 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The thirteenth and fifteenth round contained 1.5 μ M Enzyme, 1.5 μ M ssDNA and 15 mM NaCl. The sixteenth round contained 1.5 μ M enzyme, 1.5 μ M ssDNA and 20 mM NaCl. The seventeenth and twenty-first round contained 1.5 μ M enzyme, 1.5 μ M ssDNA and 50 mM NaCl.

[0035] Figure 21 shows a PCR of ssDNA from the twenty-first round of SELEX. The condition of the PCR was described in Methods. The first lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The band excised was chosen because its migration on the 8 M urea gel matched the migration of the initial random ssDNA.

[0036] Figure 22 shows a determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by the 30-mer. The enzyme was incubated in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0037] Figure 23 shows a Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by the 30-mer. Filled circle: $[I] = 0$ nM; open circle: $[I] = 1$ nM; filled square: $[I] = 2$ nM; open square: $[I] = 3$ nM. $I =$ the 30-mer.

[0038] Figure 24 shows a slope replot to estimate K_i for the 30-mer. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 23 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0039] Figure 25 shows a intercept replot to estimate K_i' for the 30-mer. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 23 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0040] Figure 26 shows a time-dependence of inactivation of *B. cereus* 5/B/6 metallo- β -lactamase activity by the 30-mer. The concentration of the 30-mer was 0.5 nM. Incubation and assay buffer was 50 mM MOPS, pH = 7.0. cephalosporin C was used as substrate. Open circle: $[I] = 0$ nM; filled circle: $[I] = 0.5$ mM. $I =$ the 30-mer.

[0041] Figure 27 shows effect of various concentrations of the 30-mer on *B. cereus* 569/H/9 β -lactamase I activity. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (benzylpenicillin) was 1.1 mM.

[0042] Figure 28 shows inhibition of bovine carboxypeptidase A by various concentrations of the 30-mer. The enzyme was preincubated with/without the inhibitor in the buffer (0.05 M TrisHCl, pH = 7.5 with 0.5 M sodium chloride) for the 15 min. at 25°C. The concentration of the substrate (hippuryl-L-phenylalanine) was 1 mM.

[0043] Figure 29 shows a secondary structure of the 30-mer predicted by the MFold program (Zuker, 1989).

[0044] Figure 30 shows another (higher energy) secondary structure of the 30-mer predicted by the MFold program (Zuker, 1989).

[0045] Figure 31 shows a secondary structure of the 61-mer predicted by the MFold program (Zuker, 1989).

[0046] Figure 32 shows shows a secondary structure of the 10-mer predicted by the MFold program (Zuker, 1989).

[0047] Figure 33 shows a determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by the 10-mer. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0048] Figure 34 shows a Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by the 10-mer. Filled circle: $[I] = 0$ nM; open circle: $[I] = 1$ nM; filled square: $[I] = 2$ nM; open square: $[I] = 3$ nM. I = the 10-mer.

[0049] Figure 35 shows a slope replot to estimate K_i for the 10-mer. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 34 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0050] Figure 36 shows a intercept replot to estimate K_i' for the 10-mer. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 34 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0051] Figure 37 shows a time-dependence of inactivation of *B. cereus* 5/B/6 metallo- β -lactamase activity by the 10-mer. The concentration of the 30-mer was 0.5 nM.

Incubation and assay buffer was 50 mM MOPS, pH = 7.0. cephalosporin C was used as substrate. Open circle: [I] = 0 nM; filled circle: [I] = 0.5 nM. I = the 10-mer.

[0052] Figure 38 shows effect of various concentrations of the 10-mer on *B. cereus* 569/H/9 β -lactamase I activity. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (benzylpenicillin) was 1.1 mM.

[0053] Figure 39 shows the effect of various concentrations of the 10-mer on bovine carboxypeptidase A. The enzyme was preincubated with/without the inhibitor in the buffer (0.05 M TrisHCl, pH = 7.5 with 0.5 M sodium chloride) for the 15 min. at 25 °C. The concentration of the substrate (hippuryl-L-phenylalanine) was 1 mM.

[0054] Figure 40 shows inhibition of for *B. cereus* 5/B/6 metallo- β -lactamase by various concentrations of the 18-mer. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0055] Figure 41 shows a determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase in the presence of Zn^{2+} ions by the 10-mer. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS and 1mM $ZnSO_4$, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

SUMMARY

[0056] One aspect of the current invention is a method for identifying a high affinity nucleic acid ligand to inhibit the activity of a lactamase enzyme. The method comprises several steps that initially involve preparing a candidate mixture of nucleic acids. The candidate mixture of nucleic acids is then allowed to make contact with the lactamase enzyme under controlled conditions of temperature, ionic strength and pH; the combination forms a candidate-enzyme mixture. Not all candidates bind tightly to the enzyme. The target nucleic acids may be easily partitioned from the remainder of the candidate mixture. Partitioning the target-nucleic acids from the remainder of the candidate mixture can be performed by many methods known to one skilled in the art. Once the target nucleic acids have been partitioned, they can be amplified to yield a pool of nucleic acids enriched with target nucleic acid sequences. The enriched pool of target nucleic acids have a relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase may be identified through methods known to one skilled in the art of molecular biology (e.g. DNA sequencing).

[0057] Another aspect of the current invention involve nucleic acid ligands that inhibit an activity of lactamase. In a preferred embodiment, the lactamase is a class B, metallo- β -lactamase. Another preferred embodiment includes a specific nucleic acid ligands that inhibit *B. cereus* 5/B/6 metallo- β -lactamase. Yet another preferred embodiment includes a specific nucleic acid ligands that inhibit *B. cereus* 569/H/9 metallo- β -lactamase.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0058] *Terms:*

[0059] "Nucleic Acid Ligand" as used herein is a non-naturally occurring nucleic acid having a desirable action on a target. A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way which modifies/alters the target or the functional activity of the target, covalently attaching to the target as in a suicide inhibitor, facilitating the reaction between the target and another molecule. In the preferred embodiment, the action has specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand, wherein the nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. The target molecule in a preferred embodiment of this invention is a lactamase. Nucleic acid ligands include nucleic acids that are identified from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of a given target by the method comprising: a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids.

[0060] "Candidate Mixture" is a mixture of nucleic acids of differing sequence from which to select a desired ligand. The source of a candidate mixture can be from naturally occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a combination of the foregoing techniques. In a preferred embodiment, each nucleic acid has fixed sequences surrounding a randomized region to facilitate the amplification process.

[0061] "Nucleic Acid" means either DNA, RNA, single-stranded or double-stranded and any chemical modifications thereof. Modifications include, but are not limited to, those that provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or

to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping.

[0062] "SELEX" methodology involves the combination of selection of nucleic acid ligands that interact with a target in a desirable manner, for example binding to a protein, with amplification of those selected nucleic acids. Iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids that interact most strongly with the target from a pool that contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued until a selected goal is achieved. In the present invention, the SELEX methodology is employed to obtain nucleic acid ligands to a lactamase enzyme.

[0063] "Target" means any compound or molecule of interest for which a ligand is desired. A target can be a protein, peptide, carbohydrate, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, etc. without limitation. In this application, the target is a lactamase. In a preferred embodiment the lactamase is a class B metallo-lactamase.

[0064] A "labile ligand" as used herein means a nucleic acid ligand identified by the SELEX process that has a greatly decreased affinity for its target based on an adjustment of an environmental parameter. In the preferred embodiment, the environmental parameter is temperature, and the affinity of a ligand to its target is decreased at elevated temperatures.

[0065] One aspect of the current invention is a method for identifying a high affinity nucleic acid ligand to inhibit the activity of a lactamase enzyme. The method comprises several steps that initially involve preparing a candidate mixture of nucleic acids. The candidate mixture of nucleic acids is then allowed to make contact with the lactamase enzyme under controlled conditions of temperature, ionic strength and pH; the combination

forms a candidate-enzyme mixture. Not all candidates bind tightly to the enzyme. The target nucleic acids may be easily partitioned from the remainder of the candidate mixture. Partitioning the target-nucleic acids from the remainder of the candidate mixture can be performed by many methods known to one skilled in the art. Once the target nucleic acids have been partitioned, they can be amplified to yield a pool of nucleic acids enriched with target nucleic acid sequences. The enriched pool of target nucleic acids have a relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase may be identified through methods known to one skilled in the art of molecular biology (e.g. DNA sequencing).

[0066] Another aspect of the current invention involve nucleic acid ligands that inhibit an activity of lactamase. In a preferred embodiment, the lactamase is a class B, metallo- β -lactamase. In another preferred embodiment, the class B lactamase includes a B anthracis metallo- β -lactamase. Another preferred embodiment includes a specific nucleic acid ligands that inhibit *B. cereus* 5/B/6 metallo- β -lactamase. Yet another preferred embodiment includes a specific nucleic acid ligands that inhibit *B. cereus* 5/H/9 metallo- β -lactamase.

[0067] MATERIALS AND METHODS:

[0068] Metallo- β -lactamase. The metallo- β -lactamase from *B. cereus* 5/B/6 was produced from *E. coli* MZ1 carrying the pRE2/bla plasmid and purified according to the procedures described previously (Shaw et al, 1991). The purity was ascertained by specific activity, native and SDS PAGE, and DE-MALDI-TOF. T4 DNA ligase was purchased from Promega. Restriction endonucleases NdeI and SacI were purchased from New England Biolabs, Inc. and were used according to the manufacturer's recommendations. DNA molecular weight markers (BstNI digested pBR322 and BstEII digested λ DNA) were purchased from New England Biolabs, Inc. The QuikChange Site-directed mutagenesis kit was purchased from Stratagene. DEAE-Sephacel, Sephadex G-25 (superfine), CM-Sephadex CL 6B and various columns were purchased from Pharmacia or Bio-Rad Laboratories. The Gene Clean II Kit was purchased from BIO101. Automated DNA sequencing was done on ABI PRISMTM 310 Genetic Analyzer from Applied Biosystems Inc. Synthetic oligonucleotides for SELEX were synthesized using Beckman Oligo 1000M oligonucleotide synthesizers. PCR reactions were carried out using a Perkin Elmer Certus Thermal Cycler. *Pfu*

polymerase was purchased from Stratagene. The cell suspensions were sonicated using a Heat System Ultrasonics, Inc. model W-375 sonicator. PCI (Phenol: Chloroform: Isoamyl alcohol (25:24:1) and electrophoresis grade agarose were obtained from Amresco. Bovine carboxypeptidase A and hippuryl-L-phenylalanine were purchased from Sigma. PCR 20 bp low ladder, ethidium bromide, dimethylsulfoxide (DMSO), acrylamide, bisacrylamide, benzylpenicillin, cephalosporin C (potassium salt), ampicillin, cesium chloride, EDTA, ethanol, glucose, sodium hydroxide, potassium hydroxide, rubidium chloride, urea, MOPS, Tris, ZnSO_4 and various other inorganic salts and organic solvents of reagent grade or better were obtained from Sigma Chemical Co. Difco brand bacto-agar, casamino acids and yeast extract used to make all media and plates were obtained through Fisher Scientific.

[0069] Method for assay of the purified *B. cereus* 5/B/6 metallo- β -lactamase and *B. cereus* 568/H/9 β -lactamase I. For metallo- β -lactamase activity assays, the activities using cephalosporin C as substrate were determined as previously reported (Myers and Shaw, 1989). The activity assay procedure was essentially the same as the spectrophotometric method of Davies et al. (1974) in which the substrate absorbance at 260 nm is continuously monitored during hydrolysis. One unit of activity was defined as the amount of enzyme required to catalyze the hydrolysis of 1 μmol of substrate in one minute at 30°C. All assays were carried out near V_{max} using 4.3 mM cephalosporin C (approximately 10 K_m) dissolved in 50 mM MOPS/1 mM ZnSO_4 , pH = 7.0. The assays were performed in a 0.1 cm pathlength quartz cuvette and the total reaction volume was maintained at 250 μL .

[0070] For β -lactamase I activity assays, Davies et al. (1974) described the method of β -lactamase I activity assays. The method was modified. The enzyme sample was incubated with 20 mM EDTA (pH = 7.0) for 15 min. at room temperature prior to the assay. The enzymatic hydrolysis of 1.1 mM benzylpenicillin in 10 mM sodium citrate (pH = 7.0) and 1 mM EDTA was continuously monitored at 231 nm at 30°C. One unit of β -lactamase activity was defined as the amount of enzyme required to hydrolyze one μmole of substrate/min. at 30°C at pH = 7.0. The protein concentrations were determined by the method of Lowry (Lowry et al., 1951) using bovine serum albumin as a standard. This method was used throughout for all protein determinations.

[0071] **Method for reversible inhibition studies for metallo- β -lactamase.** To test reversible inhibitors, the preincubation mixtures contained possible inhibitors in 50 mM MOPS buffer, pH = 7.0 at 30°C for 15 minutes. The metallo- β -lactamases were incubated with the same final concentration of the possible inhibitors as the preincubation mixture in 50 mM MOPS buffer (pH = 7.0) for 15 minutes. The enzyme activity remaining was determined (Myers and Shaw, 1989).

[0072] **Method for SELEX Oligonucleotides.** In 1990, the laboratories of G.F. Joyce (La Jolla), J.W. Szostak (Boston), and L. Gold (Boulder) independently developed a technique, which allows the simultaneous screening of a large number of nucleic acid molecules for different functionalities. This method is commonly known as '*in vitro* selection' (Ellington and Szostak, 1990), '*in vitro* evolution' (Joyce, 1989), or 'SELEX' (Systematic Evolution of Ligands by Exponential enrichment) (Tuerk and Gold, 1990). With the *in vitro* selection technique large random pools of nucleic acids can be screened for a particular functionality, such as the binding to small organic molecules (Famulk, 1994), large proteins (Tuerk and Gold, 1990; Chen and Gold, 1994) or the alteration or *de novo* generation of ribozyme catalysis (Robertson and Joyce, 1990; Bartel and Szostak, 1993). Functional molecules ('aptamers' from 'aptus'; lat. = to fit) are selected from the mainly non-functional pool of RNA or DNA by column chromatography or other selection techniques that are suitable for the enrichment of any desired property.

[0073] The method is conceptually straightforward: a starting, degenerate oligonucleotide pool is generated using a standard DNA-oligonucleotide synthesizer. The instrument synthesizes an oligonucleotide with a completely random base-sequence, which is flanked by defined primer binding sites. The immense complexity of the generated pool justifies the assumption that it may contain a few molecules with the correct secondary and/or tertiary structures that bind tightly and specifically to a target enzyme and inhibit the enzymatic activity. These are selected, for example, by affinity chromatography or filter binding. Because a pool of such high complexity can be expected to contain only a very small fraction of functional molecules, several purification steps are usually required. Therefore, the very rare "active" molecules are amplified by the polymerase chain reaction ("PCR"). In this way, iterative cycles of selection can be carried out. Successive selection and amplification cycles result in an exponential increase in the abundance of functional sequences, until they

dominate the population. A generalized diagram of the SELEX protocol is shown in Figure 4, which shows a diagrammatic representation of the SELEX procedure (modified from Gold et al., 1995). The primer sequences permit amplification, and in its most basic form, the SELEX process may be defined by the following series of steps:

[0074] 1) A candidate mixture of nucleic acids of differing sequence is prepared. The candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are selected either: (a) to assist in the amplification steps described below, (b) to mimic a sequence known to bind to the target, or (c) to enhance the concentration of a given structural arrangement of the nucleic acids in the candidate mixture. The randomized sequences can be totally randomized (i.e., the probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any level between 0 and 100 percent).

[0075] 2) The candidate mixture is contacted with the selected target under conditions favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target.

[0076] 3) The nucleic acids with the highest affinity for the target are partitioned from those nucleic acids with lesser affinity to the target. Because only an extremely small number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a significant amount of the nucleic acids in the candidate mixture (approximately 5-50%) are retained during partitioning.

[0077] 4) Those nucleic acids selected during partitioning as having the relatively higher affinity to the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target.

[0078] 5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer unique sequences, and the average degree of affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule.

[0079] US patent 5,637,459 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric Selex" issued on June 30, 1998 with Burke et al., listed as inventors, and 5,773,598 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric Selex" issued on June 30, 1998 with Burke et al., listed as inventors, both of these patents describe and elaborate on the SELEX process in great detail. Both cited patents are herein incorporated by reference. Included are targets that can be used in the process; methods for partitioning nucleic acids within a candidate mixture; and methods for amplifying partitioned nucleic acids to generate enriched candidate mixture. The SELEX Patents also describe ligands obtained to a number of target species, including both protein targets where the protein is and is not a nucleic acid binding protein.

[0080] The SELEX process provides high affinity ligands of a target molecule. Oligonucleotides were produced using a Beckman Instruments, Inc. OLIGO 1000M DNA synthesizer. One 61 base single-stranded DNA was synthesized containing 30 bases of randomized sequence ("30N") between two primer regions encompassing SacI and NdeI recognition sites. This template DNA was then amplified by PCR with the corresponding primers SeqID#1 that is a 5' Primer (16-mer) with a NdeI restriction site (e.g. 5'GCGCCATATGCGCGCG3') and SeqID#2 that is a 3' Primer (15-mer) with a SacI restriction site (e.g. 5'CGCGAGCTCCCGCGCG3').

[0081] For this invention, a pool of $4^{30} = 1.2 \times 10^{18}$ 61-mer oligonucleotides were synthesized to have 15 and 16 nucleotides to serve as polymerase chain reaction ("PCR") primers at their 5' and 3' termini respectively, and also contain an internal 30-nucleotide completely random sequence. Single-stranded DNA has been selected that not only binds tightly and specifically to the *B. cereus* 5/B/6 metallo- β -lactamase, but also is able to inhibit this enzyme.

[0082] **Prediction of secondary structure of aptamers.** The MFold program is an adaptation of the *mfold* package (version 2.3) by Zuker (1989) and Jaeger et al. (1989, 1990) that has been modified to work with the Wisconsin PackageTM. Their method uses the energy rules developed by Turner et al. (1988) to predict optimal secondary structures for a RNA molecule and the energy rules compiled and developed by Allawi and SantaLucia (1997) to predict optimal and suboptimal secondary structures for a single-stranded DNA molecule. This approach will provide a first-approximation prediction of secondary structure from sequence.

[0083] **Gel shift assay.** The electrophoretic mobility shift assay used 6% (w/v) polyacrylamide gels (29:1 mono:bis) in 20 mM Tris-acetate (TA) buffer (pH = 7.0), polymerized with 0.07% (w/v) ammonium persulfate and 0.028% (v/v) TEMED. The stock enzyme in 150 mM ammonium sulfate, 10 mM sodium citrate (pH = 7.0), 1 mM ZnSO₄, and 30% (v/v) glycerol, was heated for 30 min at 60°C to denature any possible other proteins. This enzyme is stable at 60°C. The enzyme was centrifuged and the supernatant was collected. The enzyme was diluted with dilution buffer (20 mM TA and 1 mM ZnSO₄, pH = 7.0). The synthesized library of 61-mer ssDNA described above was used for SELEX selection. The ssDNA was incubated with the enzyme at 30°C for 15 min in TA buffer with an appropriate concentration of NaCl. The total reaction volume was 20 µL. The amounts of the ssDNA, enzyme and NaCl in the incubated buffer were adjusted (Table 1). After 15 min, 40% (v/v) glycerol was added to samples to give 10% (v/v) glycerol as a final concentration. Samples were run in the 6% (w/v) polyacrylamide gel at 200 V for 25 to 30 minutes. From the seventeenth round to the twenty-first round, the time period of the incubation of ssDNA and enzyme was 2.5 hours.

[0084] Table 1. Salt concentration conditions of SELEX.

Round	ssDNA	Enzyme	NaCl
1	3 µM	20µM	10 mM
2	3 µM	20 µM	10 mM
3	1.5 µM	20 µM	10 mM
4	1.5 µM	10 µM	10 mM
5	1.5 µM	10 µM	10 mM

6	1.5 μ M	5 μ M	10 mM
7	1.5 μ M	5 μ M	10 mM
8	1.5 μ M	2 μ M	10 mM
9	1.5 μ M	1.5 μ M	10 mM
10	1.5 μ M	1.5 μ M	10 mM
11	1.5 μ M	1.5 μ M	10 mM
12	1.5 μ M	1.5 μ M	10 mM
13	1.5 μ M	1.5 μ M	15 mM
14	1.5 μ M	1.5 μ M	15 mM
15	1.5 μ M	1.5 μ M	15 mM
16	1.5 μ M	1.5 μ M	20 mM
17	1.5 μ M	1.5 μ M	50 mM
18	1.5 μ M	1.5 μ M	50 mM
19	1.5 μ M	1.5 μ M	50 mM
20	1.5 μ M	1.5 μ M	50 mM
21	1.5 μ M	1.5 μ M	50 mM

[0085] The enzyme:ssDNA complexes were separated from free DNAs on the 6% (w/v) polyacrylamide gels described above. The resulting gel was soaked in the incubation buffer with the ethidium bromide for 10 minutes and was destained in ddH₂O. The enzyme:ssDNA complexes were visualized by UV illumination using TM-36 Chromato-UVE transilluminator from UVP Inc. and were excised. The ssDNA was extracted by the modified crush and soak method (Maxam and Gilbert, 1977) with the following modifications: After cutting out the segment of the gel using a sharp scalpel or razor blade, the slice was transferred to a microcentrifuge tube. The slice was crushed by a disposable pipette tip. The slice was weighed to determine its volume and 1-2 volumes of elution buffer (0.5 M ammonium acetate, 1 mM EDTA (pH = 8.0), and 0.1% (w/v) SDS) was added. The tube was incubated at 45°C on a rotary platform for 2.5 - 3 hours. After centrifuging the tube at 12,000 g for 1 minute, the supernatant was transferred to a fresh microcentrifuge tube. To avoid any fragments of polyacrylamide, a plastic column containing glass wool was used to centrifuge the supernatant. A one-half volume aliquot of elution buffer was added to the remaining

pellet to be vortexed and recentrifuged. The supernatant and gel fragments were poured into the plastic column and spun for 15 seconds. 2 - 2.5 volumes of 100% ethanol was added to the sample from this column and placed at -20°C for 1 hour and at -80°C for 10 - 15 minutes. The tube was spun for 10 - 15 minutes. This ethanol precipitation step will help the removal of ethidium bromide to provide the right conformation of ssDNA. The supernatant was discarded. The pellet was washed with 70% ethanol and was dried.

[0086] **Generation of single-stranded DNA by asymmetric PCR.** The ssDNA was subjected to amplification with 2.5 units of the *pfu* polymerase. The reaction mixture, including 200 ng of 5' primer (16mer) and 100 ng of 3' primer (15mer), was subjected to 30 cycles of 45 seconds at 94°C, 45 seconds at 55°C, and 6 seconds at 72°C. This was followed by ten minutes at 72°C to allow all annealed primers to finish extending. The optimal 10x buffer for PCR was 100 mM Tris-HCl (pH = 8.8), 35 mM MgCl₂ and 250 mM KCl. The final concentration of dNTP was 2 mM. The total reaction volume was 100 µL.

[0087] The PCR products were purified from 12% (w/v) polyacrylamide gel (29:1 mono:bis). To confirm that the PCR product was ssDNA containing a 30 base insertion, the initial pool of ssDNA containing 30 random bases was compared with the PCR product on 12% (w/v) polyacrylamide (29:1 mono:bis) and 8 M urea gel in TBE buffer (Sambrook et al., 1989).

[0088] **Cloning and sequencing.** The plasmid pRE2/bla was digested with restriction endonucleases NdeI and SacI (Reddy, Peterkofsky and McKenney, 1989). All these double-digestion mixtures were electrophoretically separated on 1.0% (w/v) agarose gel in TBE buffer at 60 V in the absence of ethidium bromide for 3 hours. The linearized pRE2 vector and the metallo-β-lactamase gene fragment were then located by staining the gels in 5 µg/mL ethidium bromide solution and visualized under UV. The restricted linear pRE2 and the metallo-β-lactamase gene fragment were then excised from the gels, and the DNAs were extracted by the Gene Clean Kit (purchased from BIO 101).

[0089] The ssDNA was amplified by PCR to make dsDNA. After ethanol precipitation, the fixed regions was digested with restriction endonuclease NdeI and SacI. The

digested fragment was loaded on 12% (w/v) polyacrylamide gels (29:1 mono:bis) and was then purified by the modified crush and soak method.

[0090] Ligation of the fragments with the linear pRE2 vector was accomplished with T4 DNA ligase (purchased from Promega Co.) at 4 °C overnight or at room temperature for 3 hours. For each ligation, 100 ng of linearized pRE vector, 1.11 ng of fragment and 3 units of T4 DNA ligase were mixed together in ligation buffer in a total volume of 10 µL. After incubation, the mixture was used to transform *E. coli* strain TAP 56 competent cell prepared by the Hanahan method (Hanahan, 1983). Transformed cells were incubated at 30°C for 2 - 5 hours and were then put into LB medium that contained 1.0% (w/v) casamino acids, 0.5% (w/v) yeast extract, 0.5% (w/v) sodium chloride (adjusted to pH = 7.0 with NaOH) and 50 µg/mL ampicillin. The culture was incubated at 30°C overnight. The subcloned plasmid DNA was prepared by the boiling miniprep method (Sambrook et al., 1989). The DNA extracted by boiling miniprep was sequenced by an ABI PRISM™ 310 Genetic Analyzer. After finding the sequence, the 30-mer insertion was synthesized by on a Beckman Instruments Inc. OLIGO 1000M DNA synthesizer. The synthesized 30-mer was purified by 12% (w/v) polyacrylamide gel for all further experiments.

[0091] Method for assay of bovine carboxypeptidase A. The assay of bovine carboxypeptidase A is based on the method of Folk and Schirmer (1963). The rate of hydrolysis of hippuryl-L-phenylalanine is determined by monitoring the increase in absorbance at 254 nm (25°C, pH = 7.5). The enzyme was dissolved in 10% lithium chloride to a concentration of 1 - 3 units per mL. Hippuryl-L-phenylalanine (0.001 M) was dissolved in 0.05 M TrisHCl, pH = 7.5 with 0.5 M sodium chloride. In a 1 cm of cuvette, 1.0 mL of substrate was added and incubated in the spectrophotometer at 25°C for 3 - 4 minutes to reach temperature equilibration and establish blank rate. Fifty µL of diluted enzyme was added to record increase in A_{254} . The enzyme was preincubated with/without the inhibitor in the buffer for 15 min. at 25 °C.

[0092] The invention may be better understood with reference to the following examples, which are representative of some of the embodiments of the invention, and are not intended to limit the invention.

EXAMPLE 1

INHIBITION STUDIES

[0093] As a preliminary control study, EDTA (Figures 5, 6, 7 and 8) and 2-mercaptoethanol (Figures 9, 10, 11 and 12) were tested. The data is presented in Table 2. From the kinetic study, EDTA and 2-mercaptoethanol showed noncompetitive inhibition (Figures 6 and 10). The values of K_i (dissociation constant for the inhibitor from the enzyme-inhibitor complex) and K_i' (dissociation constant for the inhibitor from the enzyme-substrate-inhibitor complex) as determined by slope and intercept replots (Figures 7, 8, 11 and 12) are listed in Table 2.

[0094] The IC_{50} value, that represents the concentration of inhibitor required to affect a 50% loss of activity of free enzyme, was determined by measuring the rate of enzymatic hydrolysis of cephalosporin C after the enzyme has been preincubated for 15 minutes and assayed in presence of different amounts of inhibitor. The IC_{50} values of EDTA, 2-mercaptoethanol, compounds 6 and 7 were 3.1 μ M and 4.0 μ M, respectively (Table 2),

[0095] Figure 5. Determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by EDTA. The enzyme was preincubated with/without EDTA in the buffer (50 mM MOPS, pH = 7.0) for 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0096] Figure 6. Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by EDTA. Open square: $[I] = 0 \mu$ M; open circle: $[I] = 3 \mu$ M; filled square: $[I] = 4 \mu$ M; filled diamond: $[I] = 5 \mu$ M. $I = \text{EDTA}$.

[0097] Figure 7. Slope replot to estimate K_i for EDTA. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 6 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0098] Figure 8. Intercept replot to estimate K_i' for EDTA. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 6 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0099] Figure 9. Determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by 2-mercaptoethanol. The enzyme was preincubated with/without 2-mercaptoethanol in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0100] Figure 10. Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by 2-mercaptoethanol. Open square: $[I] = 0 \mu M$; filled square: $[I] = 3 \mu M$; open circle: $[I] = 4 \mu M$; filled diamond: $[I] = 5 \mu M$; open triangle: $[I] = 6 \mu M$. $I = 2$ -mercaptoethanol.

[0101] Figure 11. Slope replot to estimate K_i for 2-mercaptoethanol. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 10 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0102] Figure 12. Intercept replot to estimate K_i' for 2-mercaptoethanol. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 10 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0103] Table 2. Reversible inhibition of *B. cereus* 5/B/6 metallo- β -lactamase.

	IC_{50}	K_i	K_i'
EDTA	3.1 μM	0.75 μM	2.9 μM

2-mercaptoethanol	4.0 μ M	2.0 μ M	4.0 μ M
-------------------	-------------	-------------	-------------

EXAMPLE 2

COMBINATORIAL APPROACH TO INHIBITION OF METALLO- β -LACTAMASES: SELEX

[0104] A pool of 4^{30} (1.2×10^{18}) 61-mer oligonucleotides, that share 15 and 16 nucleotide sites for polymerase chain reaction (PCR) primers at their 5' and 3' termini respectively and also contain an internal random sequence 30-nucleotide was synthesized.

[0105] After incubating the enzyme with the pool of 61-mer oligonucleotides, the enzyme:ssDNA complex was separated from free ssDNA by electrophoresis.

[0106] Figure 13 shows the existence of a nucleic acid:protein complex and was obtained by staining in ethidium bromide and Coomassie Brilliant Blue R250. The *B. cereus* 5/B/6 metallo- β -lactamase is a cationic enzyme. If there were no ssDNA binding to the enzyme, the enzyme would not migrate into the gel but would rather travel up the gel toward the cathode and out of the sample well area. The bound ssDNA provides negative charges for migration down the gel toward the anode. The bound ssDNA can be recognized by ethidium bromide fluorescence and the protein can be identified by Coomassie Brilliant Blue R250.

[0107] In Figure 14, the PCR products from SELEX migrated differently compared from the initial random ssDNA. This difference of migration and the broad nature of band of the PCR products can be due to the variety of possible secondary and tertiary structures of the PCR products.

[0108] To confirm that the excised band from the PCR products contained the sought-for ssDNA, the initial random ssDNA was compared with the ssDNA generated by PCR after SELEX on an 8 M urea gel (Figure 15). The results of the comparison showed that the electrophoretic migration of the ssDNA after SELEX was essentially identical to that of the initial random ssDNA.

[0109] A significant advantage of the electrophoretic separation is that it allows visualization of each selection step, making apparent the relative amounts of bound and free DNA. It thus indicates the stringency of selection and reveals whether ligand binding has occurred during the course of an experiment. In the early rounds (Figure 16), the enzyme was in excess, so location of the enzyme:ssDNA complex was easily accomplished. The ratio of enzyme:ssDNA in early rounds was 6.7. The ratio was then gradually decreased to give more stringency of selection in the middle rounds (Figure 18). The ratio of enzyme:ssDNA was 3.3, 3.3 and 1.3 at rounds 6, 7 and 8 respectively. The gel showed an enzyme:ssDNA complex (Figure 18) that was more intense than the band corresponding to free DNA. From the ninth round, the ratio of enzyme:ssDNA was maintained at 1:1. The concentration of the NaCl added was increased to 15 mM from 10 mM at the thirteenth round. In the late rounds, free ssDNA was the predominately visible species in the gel (Figure 20). In the sixteenth round, although the concentration of NaCl was increased up to 20 mM NaCl, free ssDNA was significantly diminished due to selection of high affinity of the ssDNA for the enzyme (Figure 20).

[0110] The PCR products of ssDNA were located between 20 bps and 40 bps (Figures 17, 19 and 21). To test whether the ssDNA could bind and inhibit the enzyme, a preliminary inhibition test was performed at the eighth, eleventh, fourteenth and sixteenth rounds. The results of preliminary inhibition study are summarized in Table 3.

[0111] At round 8, 40% inactivation occurred. After round 11, the inactivation increased to 75%. The inactivation of round 11 was very close to round 14. The inactivation of round 16, however, decreased to 53%. In this preliminary inhibition test, the results were not accurate because the concentration of ssDNA was estimated optically based on the intensity of florescence compared to the sample of ssDNA of known concentration.

[0112] After the sixteenth round, cloning of the fragment into the vector pRE2 was carried out. This made it possible to sequence the insert. The sequence was SeqID# 3 - 5'-d(ANCNANNNTTNNNTNGNNGNNCATNNNNAA)-3', which contained 17 N's. To give more stringency of selection, beginning with the seventeenth round, the concentration of NaCl was increased to 50 mM. Also, the incubation time was increased to 2.5 hours. This resulted in a smearing effect on the gel due to increasing the salt concentration to 50 mM

NaCl. After the twenty-first round, the cloning and sequencing were carried out again. The sequence of the 30-mer aptamer was determined to be SeqID# 4:

5'-d(AACCAAACCTTGGATCGGTGCACATGTCGAA)-3'

[0113] This final single-stranded DNA aptamer (30-mer) was synthesized using a Beckman Oligo 1000M oligonucleotide synthesizer.

[0114] The IC_{50} value for the 30-mer was determined by measuring the rate of enzymatic hydrolysis of cephalosporin C after the enzyme has been preincubated and assayed in presence of different amounts of the 30-mer. The IC_{50} of the 30-mer was 1.2 nM. The data is presented in Table 4 and Figure 22. From a steady-state kinetic study, the 30-mer showed a noncompetitive inhibition (Figure 23). The value of K_i (dissociation constant for the inhibitor from the enzyme-inhibitor complex) for the 30-mer was 0.92 nM and the value of K_i' (dissociation constant for the inhibitor from the enzyme-substrate-inhibitor complex) for the 30-mer was 11 nM as determined by slope and intercept replots (Table 4, Figures 24 and 25).

[0115] In order to check to see if the reversible inhibition was time-dependent, the time dependence of the inhibition of the enzyme by 0.5 nM the 30-mer was measured. As can be seen from Figure 26, the inhibition was time-independent.

[0116] The experiment of Figure 27 was performed to test the specificity of inhibition by this 30-mer. As can be seen in Figure 64, 100 nM of the 30-mer has no effect on the activity of the *B. cereus* 569/H/9 β -lactamase I (a class A β -lactamase).

[0117] In addition, the bovine carboxypeptidase A was used to test the specificity of inhibition by this 30-mer. As can be seen in Figure 28, 25 nM of the 30-mer has no effect on the activity of the carboxypeptidase A.

[0118] Figure 13. The evidence for a complex of the *B. cereus* 5/B/6 metallo- β -lactamase and the ssDNA. On the left, the gel was stained by ethidium bromide. On the right, the gel was stained by Coomassie Brilliant Blue R250. 20 μ M enzyme and 1.5 μ M ssDNA

were used to make the complex. The buffer used for incubation was 20 mM TA (pH = 7.0) and 1 mM ZnSO₄.

[0119] Figure 14. Comparison of the initial random ssDNA with the ssDNA after SELEX on a native gel. The first lane contained initial random ssDNA. The second lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The fourth, fifth, sixth and seventh lanes contained PCR products after the eight round of SELEX. A 12% (w/v) polyacrylamide gel (29:1 mono:bis) was used in TA buffer.

[0120] Figure 15. Comparison of the initial random ssDNA with the ssDNA after SELEX on a denaturing gel. The left lane contained ssDNA after SELEX and the right lane contained initial random ssDNA. The 12% polyacrylamide gel (29:1 mono:bis) was run with 8M urea in TBE buffer (45 mM Tris, 45 mM boric acid and 1 mM EDTA, pH = 8.0).

[0121] Figure 53. The early rounds of SELEX. The first, second, third lanes are for the first, third, fifth rounds of SELEX, respectively. The gel shift assays were carried out as described in Methods. The first round contained 20 μ M enzyme, 3 μ M ssDNA and 10 mM NaCl. The third round contained 20 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The fifth round contained 10 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl.

[0122] Figure 16. PCR of ssDNA from the first round of SELEX. The condition of the PCR was described in Methods. The first lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The band excised was chosen because its migration on the 8 M urea gel matched the migration of the initial random ssDNA.

[0123] Figure 18. The middle rounds of SELEX. The first, second, third lanes are for the sixth, seventh, eighth round SELEX, respectively. The gel shift assays were carried out as described in Methods. The sixth round contained 5 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The seventh round contained 5 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The eighth round contained 2 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl.

[0124] Figure 19. PCR of ssDNA from the ninth round of SELEX. The condition of the PCR was described in Methods. The first lane contained the molecular size

markers. The first marker from the bottom represents 20 bps. The band excised was chosen because its migration on the 8 M urea gel matched the migration of the initial random ssDNA.

[0125] Figure 20. The late rounds of SELEX. The first, second, third, fourth, fifth, sixth and seventh lanes are for the ninth, twelfth, thirteenth, fifteenth, sixteenth, seventeenth, and twenty-first round SELEX, respectively. The gel shift assays were carried out as described in Methods. The ninth and twelfth round contained 1.5 μ M enzyme, 1.5 μ M ssDNA and 10 mM NaCl. The thirteenth and fifteenth round contained 1.5 μ M Enzyme, 1.5 μ M ssDNA and 15 mM NaCl. The sixteenth round contained 1.5 μ M enzyme, 1.5 μ M ssDNA and 20 mM NaCl. The seventeenth and twenty-first round contained 1.5 μ M enzyme, 1.5 μ M ssDNA and 50 mM NaCl.

[0126] Figure 21. PCR of ssDNA from the twenty-first round of SELEX. The condition of the PCR was described in Methods. The first lane contained the molecular size markers. The first marker from the bottom represents 20 bps. The band excised was chosen because its migration on the 8 M urea gel matched the migration of the initial random ssDNA.

[0127] Table 3. Estimates of the metallo- β -lactamase activity assay in presence of selected ssDNA pools.

Inhibitor DNA	Percent control enzyme activity
Oligonucleotides before SELEX	100%
ssDNA* after the eighth round	60%
ssDNA* after the eleventh round	25%
ssDNA* after the fourteenth round	27%
ssDNA* after the sixteenth round	47%

* The approximate concentration of the ssDNA was estimated as described in the text to be 42 nM.

[0128] Figure 22. Determination of IC₅₀ for *B. cereus* 5/B/6 metallo- β -lactamase by the 30-mer. The enzyme was incubated in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0129] Figure 23. Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by the 30-mer. Filled circle: $[I] = 0$ nM; open circle: $[I] = 1$ nM; filled square: $[I] = 2$ nM; open square: $[I] = 3$ nM. $I =$ the 30-mer.

[0130] Figure 24. Slope replot to estimate K_i for the 30-mer. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 23 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0131] Figure 25. Intercept replot to estimate K_i' for the 30-mer. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 23 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0132] Figure 26. Time-dependence of inactivation of *B. cereus* 5/B/6 metallo- β -lactamase activity by the 30-mer. The concentration of the 30-mer was 0.5 nM. Incubation and assay buffer was 50 mM MOPS, pH = 7.0. cephalosporin C was used as substrate. Open circle: $[I] = 0$ nM; filled circle: $[I] = 0.5$ mM. $I =$ the 30-mer.

[0133] Figure 27. Effect of various concentrations of the 30-mer on *B. cereus* 569/H/9 β -lactamase I. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (benzylpenicillin) was 1.1 mM.

[0134] Figure 28. Inhibition of bovine carboxypeptidase A by various concentrations of the 30-mer. The enzyme was preincubated with/without the inhibitor in the buffer (0.05 M TrisHCl, pH = 7.5 with 0.5 M sodium chloride) for the 15 min. at 25°C. The concentration of the substrate (hippuryl-L-phenylalanine) was 1 mM.

[0135] Table 4. Inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by the ssDNA 30-mer.

	IC ₅₀	K _i	K _i '
Synthetic 30-mer	1.2 nM	0.92 nM	11 nM

PREDICTION OF SECONDARY STRUCTURE OF APTAMERS AND METALLO- β -LACTAMASE INHIBITION

[0136] The secondary structure of aptamers was predicted by the MFold program (Zuker, 1989). Two different secondary structures of the aptamer (30-mer) were predicted.

[0137] SeqID# 4 is a 30 mer ssDNA and is shown in Structure 1 (Figure 29) included a one stem-loop structure, and structure 2 (Figure 30) included a two stem-loop structure. Structure 1 was predicted to be lower in energy than structure 2. The sequence of the stem-loop structure from structure 1 is 5'-d(CCAAACCTTGG)-3'. This sequence is one of the two stem-loop structures from structure 2 as well. The thermodynamic parameters of folding of the aptamers were calculated by MFold program (Table 5).

[0138] The predicted secondary structure for the aptamer (61-mer) as listed in SeqID# 6 containing the primer sequence regions revealed several stem-loop structures (Figure 31). The sequence SeqID# 5, 5'-d(CCAAACCTTGG)-3', was present as a stem-loop structure in the aptamer (61-mer). This result suggests that the SeqID# 5 5'-d(CCAAACCTTGG)-3' sequence may be important for interaction with metallo- β -lactamase.

[0139] This conserved single-stranded DNA (10-mer) SeqID# 5 sequence was synthesized using a Beckman Oligo 1000M oligonucleotide synthesizer. To confirm the stem-loop structure from the conserved sequence, the secondary structure of the 10-mer was predicted by the MFold program (Zuker, 1989). From the prediction, the same stem-loop secondary structure of the 10-mer was preserved (Figure 32).

[0140] The IC₅₀ value for the SeqID# 5 10-mer was determined by measuring the rate of enzymatic hydrolysis of cephalosporin C after the enzyme has been preincubated and assayed in presence of different of amounts of the 10-mer. The data is presented in Table 6 and Figure 33.

[0141] From a steady-state kinetic study, the 10-mer SeqID# 5 showed a noncompetitive inhibition (Figure 34). The value of K_i (dissociation constant for the inhibitor from the enzyme-inhibitor complex) for the 10-mer was 0.31 nM and the value of K_i' (dissociation constant for the inhibitor from the enzyme-substrate-inhibitor complex) for the 10-mer was 1.5 nM as determined by slope and intercept replots (Table 6, Figures 35 and 36).

[0142] In order to check to see if the reversible inhibition was time-dependent, the time dependence of the inhibition of the enzyme by 1.0 nM of the 10-mer was measured. As can be seen from Figure 37, the inhibition was time-independent.

[0143] The experiment of Figure 38 was performed to test the specificity of inhibition by this 10-mer SeqID# 5. As can be seen in Figure 75, the 10-mer has no effect on the activity of the *B. cereus* 569/H/9 β -lactamase I (a class A β -lactamase).

[0144] In addition, the bovine carboxypeptidase A was used to test the specificity of inhibition by this 10-mer. As can be seen in Figure 39, 25 nM of the 10-mer has no effect on the activity of the carboxypeptidase A.

[0145] An 18-mer corresponding to the remainder of the 30-mer sequence was tested to check how much the conserved 10-mer from the prediction is responsible for the inhibition of the metallo- β -lactamase. As can be seen in Figure 40, the 18-mer did not show significant inhibition up to 50 nM.

[0146] As a control experiment, in order to check to see if the 10-mer binds to metal ion(s) in the active site of the metallo- β -lactamase, the assay for the metallo- β -lactamase was carried out in the presence of 1 mM ZnSO_4 . The IC_{50} value for the 10-mer was greatly elevated up to 32 nM because of the excess Zn^{2+} ions (Figure 41).

[0147] Figure 29. Secondary structure 1 of the 30-mer predicted by the MFold program (Zuker, 1989).

[0148] Figure 30. Secondary structure 2 of the 30-mer predicted by the MFold program (Zuker, 1989).

[0149] Figure 31. Secondary structure of the 61-mer (SeqID# 6) predicted by the MFold program (Zuker, 1989).

[0150] Table 5. Calculation of thermodynamic parameters for folding of ssDNA aptamers in 50 mM NaCl at 30°C* by MFold program

	$-\Delta G$ (kcal/mole)	$-\Delta H$ (kcal/mole)	$-\Delta S$ (cal/(K mol))	T_m (°C)
Structure 1 of the 30-mer	2.2	29.9	91.4	54.1
Structure 2 of the 30-mer	2.2	50.3	158.7	43.9
Structure of the 61-mer	11.4	123.4	369.5	60.9
Structure of the 10-mer	0.5	21.5	69.3	37.2

* Temperature and the concentration of NaCl are the same conditions as the SELEX experiments.

[0151] Figure 32. Secondary structure of the 10-mer produced by the MFold program (Zuker, 1989).

[0152] Figure 33. Determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase by the 10-mer. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0153] Figure 34. Lineweaver-Burk plot of inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by the 10-mer. Filled circle: $[I] = 0$ nM; open circle: $[I] = 1$ nM; filled square: $[I] = 2$ nM; open square: $[I] = 3$ nM. I = the 10-mer.

[0154] Figure 35. Slope replot to estimate K_i for the 10-mer. Slope values (K_m/V_{max}) for each inhibitor concentration from experimental data of Figure 34 were

determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Slope values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i$.

[0155] Figure 36. Intercept replot to estimate K_i' for the 10-mer. Intercept values ($1/V_{max}$) for each inhibitor concentration from experimental data of Figure 34 were determined using a non-linear regression computer program (EnzymeKinetics, v. 1.2, Trinity Software). Intercept values were then plotted vs. corresponding inhibitor concentrations. The x-intercept in this plot is $-K_i'$.

[0156] Figure 37. Time-dependence of inactivation of *B. cereus* 5/B/6 metallo- β -lactamase activity by the 10-mer. The concentration of the 30-mer was 0.5 nM. Incubation and assay buffer was 50 mM MOPS, pH = 7.0. cephalosporin C was used as substrate. Open circle: $[I] = 0$ nM; filled circle: $[I] = 0.5$ nM. I = the 10-mer.

[0157] Figure 38. Inhibition of *B. cereus* 569/H/9 β -lactamase I by various concentrations of the 10-mer. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (benzylpenicillin) was 1.1 mM.

[0158] Figure 39. Effect of various concentrations of the 10-mer on bovine carboxypeptidase A. The enzyme was preincubated with/without the inhibitor in the buffer (0.05 M TrisHCl, pH = 7.5 with 0.5 M sodium chloride) for the 15 min. at 25°C. The concentration of the substrate (hippuryl-L-phenylalanine) was 1 mM.

[0159] Figure 40. Inhibition of for *B. cereus* 5/B/6 metallo- β -lactamase by various concentrations of the 18-mer. The enzyme was preincubated with/without the inhibitor in the buffer (50 mM MOPS, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0160] Figure 41. Determination of IC_{50} for *B. cereus* 5/B/6 metallo- β -lactamase in the presence of Zn^{2+} ions by the 10-mer. The enzyme was preincubated with/without the

inhibitor in the buffer (50 mM MOPS and 1mM ZnSO₄, pH = 7.0) for the 15 min. at 30°C. The concentration of the substrate (cephalosporin C) was 4 mM.

[0161] Table 6. Inhibition of *B. cereus* 5/B/6 metallo- β -lactamase by the ssDNA 10-mer.

	IC ₅₀	K _i	K _i '
Synthetic 10-mer	1.2 nM	0.31 nM	1.5 nM

[0162] As a preliminary experiment, inhibition patterns for EDTA and 2-mercaptoethanol were generated. From inhibition kinetic studies, noncompetitive inhibition was shown for EDTA and 2-mercaptoethanol. EDTA is well known as a good chelating reagent for Zn²⁺ ions.

[0163] Metallo- β -lactamase inhibition studies by a combinatorial approach (SELEX). To find an inhibitor for metallo- β -lactamase, a combinatorial approach was utilized. In this study, we have taken advantage of the SELEX methodology to generate high affinity single-stranded DNA aptamers that inhibit metallo- β -lactamase activity.

[0164] To increase the stringency of selection during the course of the SELEX experiments, the concentrations of enzyme and NaCl were varied (Table 1). When the enzyme concentration was greater than the ssDNA concentration, the inhibition was approximately 40%; higher inhibition was detected after the enzyme concentration was decreased. This infers that the stringency of selection helped to eliminate non-specific binding of ssDNA. Increasing the concentration of NaCl also favored specific binding by ssDNA resulting in selection for a specific oligonucleotide sequence. As another factor in detecting aptamers, increasing the incubation time may be allowed to provide time for any conformational changes of the metallo- β -lactamase that might occur to "lock" onto the specific ssDNA strongly. In the early rounds, the bands of ssDNA PCR products on the gel were broad. The bands were getting sharper and more distinct throughout the SELEX rounds.

[0165] Following 21 rounds of SELEX, a single nucleic acid sequence was found. The 30-mer had IC_{50} of 1.2 nM. From the kinetic study, noncompetitive inhibition was indicated for the 30-mer. The K_i (dissociation constant for inhibitor from enzyme-inhibitor complex) and K_i' (dissociation constant for inhibitor from enzyme-substrate-inhibitor complex) values were 0.92 nM and 11 nM, respectively. The noncompetitive inhibition pattern was similar to the noncompetitive inhibition patterns of EDTA and 2-mercaptoethanol. Therefore, the 30-mer is likely to bind to one or more Zn^{2+} ions in the active site of the enzyme. The other possibility is that the 30-mer may interact with the enzyme in such a way as to block substrate access to the metal ions. This possibility could be tested by X-ray crystallographic analysis of the inhibited enzyme to determine the specific binding region of ssDNA.

[0166] This inhibition was not time-dependent. The 30-mer did not show any inhibition of β -lactamase I or carboxypeptidase A. Hence, the inhibition is very specific for metallo- β -lactamases. Clearly, the oligonucleotide does not recognize features in the metallo- β -lactamase that bind to the substrate. The carboxypeptidase A results show the exquisite specificity for the metal ion of metallo- β -lactamase. Carboxypeptidase A has been compared to the metallo- β -lactamase as a model for the latter enzyme, both in terms of structural and mechanistic features (Alberts et al., 1998; Bouagu et al., 1998). Hence, the demonstration that a concentration of the 30-mer that is $25 \times IC_{50}$ for the metallo- β -lactamase has no effect on either 569/H/9 β -lactamase I activity or on the activity of bovine carboxypeptidase A are profound observations regarding the specificity of inhibition.

[0167] A major point is that while this is considerable evidence that suggests that the mode of inhibition involves metal binding by the inhibitor, it is clear that the inhibitor does not indiscriminately chelate all zinc from all sources as does EDTA or other metal chelators.

[0168] Payne et al., (1997) have identified inhibitors for metallo- β -lactamase. One of a mercaptoacetic acid thiol esters series (SB216968) inhibited *Aeromonas hydrophila* CphA metallo- β -lactamase and was found to be an uncompetitive inhibitor ($K_i = 3.9 \mu M$). Yang and Crowder (1999) have also identified inhibitors for metallo- β -lactamase from *Stenotrophomonas*

multophila. They showed that N-(2'-mercaptoethyl)-2-phenylacetamide and N-benzylacetyl-D-alanylthioacetic acid were competitive inhibitors with K_i values of $50 \pm 3 \mu\text{M}$ and $1.6 \pm 0.3 \mu\text{M}$, respectively. Scrofani et al. (1999) suggested that the inhibitor 3-[2'-(S)-benzyl-3'-mercaptopropanoyl]-4-(S)-carboxy-5,5-dimethylthiazolidine, that exhibits many structural similarities to the β -lactam antibiotic ampicillin, "tightly" binds in a position similar to that thought to be occupied by β -lactam antibiotics for metallo- β -lactamase from *B. fragilis* using NMR characterization. A free sulfhydryl group of the inhibitor did not show a disulfide formation with one of the free cysteine side chains in the vicinity of the zinc-binding site. Mollard et al. (2001) showed that thiomandelic acid was a competitive inhibitor of metallo- β -lactamases with K_i values (*Bacillus cereus* enzyme) of $0.09 \mu\text{M}$ for R-thiomandelic acid and $1.28 \mu\text{M}$ for the S-isomer. To date, R-thiomandelic acid appears to be the most effective published inhibitor for metallo- β -lactamase. However, the K_i value (0.92 nM) of the 30-mer that we found was more effective than any of the others. Therefore, the 30-mer is a very promising inhibitor for metallo- β -lactamase.

[0169] Prediction of secondary structure of aptamers and metallo- β -lactamase inhibition. It is desirable that the aptamer should be as small as possible, on costs grounds, reasons of target accessibility and so on. The predicted secondary structures of the 30-mer produced by the MFold program revealed a conserved stem-loop structure. The sequence was 5'-d(CCAAACCTTGG)-3'. Hence, we synthesized the 10-mer.

[0170] The IC_{50} of the 10-mer was the same as the 30-mer. From the steady-state kinetic studies, the noncompetitive inhibition pattern was shown like the 30-mer. The IC_{50} value for the 10-mer was greatly elevated when the assay was carried out in the presence of inhibitor with exogenous Zn^{2+} ions. This supports idea that the 10-mer likely binds to the metal ion(s).

[0171] The K_i (dissociation constant for inhibitor from enzyme-inhibitor complex) and K_i' (dissociation constant for inhibitor from enzyme-substrate-inhibitor complex) values were 0.31 nM (290-fold lower than the K_i reported for R-thiomandelic acid (Mollard et al. (2001)) and 1.5 nM , respectively. The K_i and K_i' values for the 10-mer were lower than the 30-mer. This infers that the 10-mer binds the free enzyme and enzyme-

substrate complex more strongly than the 30-mer. Although not wanting to be bound by theory the SeqID# 5 10-mer comprises a more promising drug candidate than the 30-mer SeqID# 4. For example, like the 30-mer, this inhibition was not time-dependent and the 10-mer did not show any inhibition for β -lactamase I and carboxypeptidase A. Hence, the inhibition is very specific for metallo- β -lactamases as well.

[0172] The secondary structure of 10-mer, as proposed by the MFold program, correlated well with the experimental results. The conserved structure from the sequence 5'-d(CCAAACCTTGG)-3' is responsible for the inhibition of *B. cereus* 5/B/6 metallo- β -lactamase.

[0173] An example of a commercial product using SELEX technology, Eyetech Pharmaceuticals, Inc. has a product in clinical trials that is an aptamer that inhibits vascular endothelial growth factor (VEGF). The aptamer was discovered using SELEX (Jellinek et al., 1994; Ruckman et al., 1998; Willis et al., 1998). Known as EYE001, the aptamer is an oligonucleotide that acts like a high affinity antibody to VEGF. This anti-VEFG aptamer blocks vessel growth and inhibits neovascularization in pre-clinical models.

[0174] Single-stranded DNA (Bock et al., 1992; Macaya et al., 1995; Tsiang et al., 1995) was found using the SELEX process for thrombin that is a multifunctional serine protease. The DNA ligands that have quadruplex/duplex were shown to bind the fibrinogen-recognition exosite at the base of the active site cleft. The ligand inhibits thrombin-catalyzed clot formation *in vitro* (Tasset et al., 1997). Tasset et al. (1997) showed that a 15-mer containing quadruplex motif from the previous ssDNA inhibitor binds to the active cleft. Although not wanting to be bound by theory, such structural features may be important in metallo- β -lactamase inhibition as well. Although not wanting to be bound by theory, the aptamer compounds described in this invention can serve as lead compounds for a new generation of highly effective metallo- β -lactamase inhibitors.

[0175] These compositions and methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan. The scope of the ligands covered by this invention extends to all nucleic acid ligands of lactamase and metallo-lactamases. Moreover, the effective amount of the

compositions can be further approximated through analogy to compounds known to exert the desired effect.

WHAT IS CLAIMED IS:

1. A method of identifying a nucleic acid ligand to a lactamase, comprising:
 - (a) preparing a candidate mixture of nucleic acids;
 - (b) contacting the candidate mixture of nucleic acids with the lactamase enzyme, to form an candidate-enzyme mixture;
 - (c) increasing the stringency of the candidate-enzyme mixture to a predetermined salt concentration, wherein a target nucleic acids have an increased affinity to the lactamase relative to the candidate mixture at the predetermined salt concentration whereby the target nucleic acids may be partitioned from the remainder of the candidate mixture;
 - (d) partitioning the target-nucleic acids from the remainder of the candidate mixture; and
 - (e) amplifying the target nucleic acid to yield a pool of nucleic acids enriched with target nucleic acid sequences with relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase may be identified.
2. The method of claim 1, further comprising:
 - (f) repeating steps (c), (d), and (e).
3. The method of claim 1, wherein the lactamase comprises a class B lactamase.
4. The method of claim 1, wherein the class B lactamase comprises a B anthracis metallo- β -lactamase
5. The method of claim 4, wherein the metallo-lactamase comprises a *B. cereus* 5/B/6 metallo- β -lactamase.
6. The method of claim 4, wherein the metallo-lactamase comprises a *B. cereus* 569/H/9 metallo- β -lactamase.

7. The method of claim 1, wherein the nucleic acid ligand comprises a single stranded nucleic acid.
8. The method of claim 7, wherein the single stranded nucleic acid comprises deoxyribonucleic acids.
9. The method of claim 1, wherein the salt concentration is in a range of about 10mM to about 50mM.
10. The method of claim 1, wherein the candidate mixture of nucleic acids is in a range of about 1.5uM to about 3.0uM.
11. The method of claim 1, wherein the lactamase is in a range of about 1.5 μ M to about 20 μ M.
12. A method of identifying a nucleic acid ligand to a lactamase, comprising:
 - (a) preparing a candidate mixture of nucleic acids;
 - (b) contacting the candidate mixture of nucleic acids with the lactamase enzyme, to form an candidate-enzyme mixture;
 - (c) heating the candidate-enzyme mixture to a predetermined temperature, wherein a target nucleic acids have an increased affinity to the lactamase relative to the candidate mixture at the predetermined temperature whereby the target nucleic acids may be partitioned from the remainder of the candidate mixture;
 - (d) partitioning the nucleic acid ligand from the remainder of the candidate mixture; and
 - (e) amplifying the target nucleic acid to yield a pool of nucleic acids enriched with target nucleic acid sequences with relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase may be identified.
13. The method of claim 12, further comprising:
 - (f) repeating steps (c), (d), and (e).

14. The method of claim 12, wherein the lactamase comprises a class B lactamase.
15. The method of claim 14, wherein the class B lactamase comprises a metallo- β -lactamase.
16. The method of claim 15, wherein the metallo-lactamase comprises a *B. cereus* 5/B/6 metallo- β -lactamase.
17. The method of claim 15, wherein the metallo-lactamase comprises a *B. cereus* 569/H/9 metallo- β -lactamase.
18. The method of claim 12, wherein said candidate mixture of nucleic acids comprises a single stranded nucleic acid.
19. The method of claim 18, wherein the single stranded nucleic acid comprises deoxyribonucleic acid.
20. The method of claim 12, wherein the salt concentration is in a range of about 10mM to about 50mM.
21. The method of claim 12, wherein the candidate mixture of nucleic acids is in a range of about 1.5 μ M to about 3.0 μ M.
22. The method of claim 12, wherein the lactamase is in a range of about 1.5 μ M to about 20 μ M.
23. A composition of matter comprising: a nucleic acid ligand to a lactamase.
24. The composition of claim 23, wherein the lactamase comprises a class B lactamase.
25. The composition of claim 24, wherein the class B lactamase comprises a metallo- β -lactamase.

26. The composition of claim 25, wherein the metallo-lactamase comprises a *B. cereus* 5/B/6 metallo- β -lactamase.
27. The composition of claim 25, wherein the metallo-lactamase comprises a *B. cereus* 569/H/9 metallo- β -lactamase.
28. The composition of claim 23, wherein said candidate mixture of nucleic acids is comprised of a single stranded nucleic acid.
29. The composition of claim 28, wherein the single stranded nucleic acid comprises deoxyribonucleic acid.
30. A composition of matter comprising: a nucleic acid ligand with affinity toward a lactamase.
31. The composition of claim 30, wherein the lactamase comprises a class B lactamase.
32. The composition of claim 31, wherein the class B lactamase comprises a metallo- β -lactamase.
33. The composition of claim 32, wherein the metallo-lactamase comprises a *B. cereus* 5/B/6 metallo- β -lactamase.
34. The composition of claim 32, wherein the metallo-lactamase comprises a *B. cereus* 569/H/9 metallo- β -lactamase.
35. The composition of claim 30, wherein the nucleic acid ligand comprises a single stranded nucleic acid.
36. The composition of claim 35, wherein the single stranded nucleic acid comprises deoxyribonucleic acid.
37. A composition of matter comprising a nucleic acid ligand with SEQID# 4.

38. The composition of claim 37, wherein the nucleic acid ligand inhibits a lactamase.
39. The composition of claim 38, wherein the lactamase comprises a class B lactamase.
40. The composition of claim 39, wherein the class B lactamase comprises a metallo- β -lactamase.
41. The composition of claim 40, wherein the metallo-lactamase comprises a *B. cereus* 5/B/6 metallo- β -lactamase.
42. A composition of matter comprising a nucleic acid ligand with SEQID# 5.
43. The composition of claim 42, wherein the nucleic acid ligand inhibits a lactamase.
44. The composition of claim 43, wherein the lactamase comprises a class B lactamase.
45. The composition of claim 44, wherein the class B lactamase comprises a metallo- β -lactamase.
46. The composition of claim 45, wherein the metallo-lactamase comprises a *B. cereus* 5/B/6 metallo- β -lactamase.
47. A composition of matter comprising a nucleic acid ligand with SEQID# 6.

The entire content of each of the following patents and publications are hereby incorporated by reference herein.

U.S. PATENT DOCUMENTS

- US Patent 5,637,459 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric Selex" issued on June 30, 1998 with Burke et al., listed as inventors.
- US Patent 5,773,598 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric Selex" issued on June 30, 1998 with Burke et al., listed as inventors.

REFERENCES CITED

- Abraham, E. P. and Waley, S. G. (1979) " β -Lactamases from *Bacillus cereus*", in *Beta-Lactamases* (Hamilton-Miller, J. M. T. and Smith, J. T., eds.) pp. 311-338, Academic Press, New York.
- Alberts, I. L., Katalin, N. and Wodak, S. J. (1998), "Analysis of Zinc Binding Sites in Protein Crystal Structures", *Protein Science* 7, 1700-1716.
- Allawi, H. T. and SantaLucia, J. Jr. (1997), "Thermodynamics and NMR of Internal G-T Mismatches in DNA", *Biochemistry* 36, 10581-10594.
- Ambler, R. P. (1980), "The Structure of β -Lactamases", *Phil. Trans. R. Soc. Lond. B* 289, 321-331.
- Ambler, R. P., Coulson, A. F. W., Frere, J. -M., Ghuyssen, J. -M., Joris, B., Forsman, M., Levesque, R. C., Triaby, G. and Waley, S. G. "A Standard Numbering Scheme for the Class A β -Lactamases", (1991) *Biochem J.* 276, 269-270.
- Ambler, R. P., Daniel, M., Fleming, J., Hermoso, J. -M., Pang, C. and Waley, S. G. (1985), "The Amino Acid Sequence of the Zinc-Requiring β -Lactamase II from the bacterium *Bacillus cereus*", *FEBS Lett.* 189, 207-211.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K. (1992), "Introduction of Plasmid DNA into Cells", in *Short Protocols in Molecular Biology* pp. 26-27, Greene Publishing Associates and Wiley-Interscience, John Wiley & Sons, New York.

- Bartel, D. P. and Szostak, J. W., (1993), "Isolation New Ribozymes from a Large Pool of Random Sequences", *Science* 261, 1411-1418.
- Bicknell, R., Schaeffer, A., Waley, S. G. and Auld, D. S. (1986), "Changes in the Coordination Geometry of the Active-Site Metal During Catalysis of Benzylpenicillin Hydrolysis by *Bacillus cereus* β -Lactamase II", *Biochemistry* 25, 7208-7215.
- Brenner, D. G. and Knowles, J. D., (1984), "Penicillanic Acid Sulfone: Nature of Irreversible Inactivation of RTEM β -Lactamase from *Escherichia coli*", *Biochemistry* 23, 5834-5846.
- Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H. and Toole, J. J. (1992), "Selection of Single-Stranded DNA Molecules that bind and Inhibit Human Thrombin", *Nature* 355, 564-566.
- Bouagu, S., Laws, A., Galleni, M. and Page, M. (1998), "The mechanism of Catalysis and the Inhibition of the *Bacillus cereus* Zinc-Dependent β -lactamase", *Biochem. J.* 331, 703-711.
- Carfi, A., Pares, S., Duee, E., Galleni, M., Duez, C., Frere, J. M. and Dideberg, O. (1995), "The 3-D Structure of a Zinc Metallo- β -lactamase from *Bacillus cereus* Reveals a New Type of Protein Fold", *The EMBO Journal*, 14, No. 20, 4914-4921.
- Chen, H. and Gold, L., (1994), "Selection of High-Affinity RNA Ligands to Reverse Transcriptase", *Biochemistry* 33, 8746-8756.
- Concha, N. O., Janson, C. A., Rowling, P., Pearson, S., Cheever, C. A., Clarke, B. P., Lewis, C., Galleni, M., Frere, J. M., Payne, D. J., Bateson, J. H. and Abdel-Meguid, S. (2000), "Crystal of the IMP-1 Metallo- β -Lactamase from *Pseudomonas aeruginosa* and its Complex with a Mercaptocarboxylate Inhibitor", *Biochemistry* 15, 4288-4298.
- Concha, N. O., Rasmussen, B. A., Bush, K. and Herzberg, O. (1996), "Crystal Structure of the Wide-Spectrum Binuclear Zinc β -Lactamase from *Bacteriodes fragilis*", *Structure* 4, 823-836.

- Crompton, B., Jago, M., Crawford, K., Newton, G. G. F. and Abraham, E. P. (1962), "Behaviour of Some Derivatives of 7-Aminocephalosporanic Acid as Substrates, Inhibitors and Inducers of Penicillanases", *Biochem J.* 83, 52-63.
- Danziger, L. H. and Pendland, S. L. (1995), "Bacterial Resistance to β -Lactam Antibiotics", *Am. J. health Syst. Pharm* 52 (Suppl 2), S3-8.
- Davies, R. B. and Abraham, E. P. (1974), "Metal Cofactor Requirements of β -Lactamase II", *Biochem J.* 143, 129-135.
- Davies, R. B. Abraham, E. P. and Melling, J. (1974), "Separation, Purification and Properties of β -Lactamase I and β -Lactamase II from *Bacillus cereus* 569/H/9", *Biochem J.* 143, 115-127.
- Davies, R. B. Abraham, E. P. Melling, J. and Pollock, M. R. (1975), "Comparison of β -lactamase II from *Bacillus cereus* 569/H/9 with a β -Lactamase from *Bacillus cereus* 5/B/6", *Biochem J.* 145, 409-411.
- Ellington A.D. and Szostak J. W. (1990), "In Vitro Selection of RNA Molecules that Bind Specific Ligands", *Nature* 346, 818-822.
- Farmulok, M. and Szostak, J. W. (1992), "In Vitro Selection of Specific Ligand Binding Nucleic Acids", *Angew. Chem. Int. Ed. Engl.* 31, 979-988.
- Felici, A. and Amicosante, G. (1995), "Kinetic Analysis of Extension of Substrate Specificity with *Xanthomonas maltophilia*, *Aeromonas hydrophilia* and *Bacillus cereus* Metallo- β -Lactamases", *Antimicrob. Agents Chemother.* 39, 192-199.
- Felici, A., Amicosante, G., Oratore, A., Strom, R., Ledent, P., Joris, B., Fanuel, L. and Frere, J. -M. (1993), "An Overview of the Kinetic Parameters of Class B β -Lactamases", *Biochem J.* 291, 151-155.
- Felici, A., Perilli, M., Franceschini, N., Rossolini, G. M., Galleni, M., Frere, J. -M., Oratore, A. and Amicosante, G. (1997), "Sensitivity of *Aeromonas hydrophilia* Carbapenemase to Δ^3 -Cephems", *Antimicrob. Agents Chemother.* 41, 866-868.

- Fisher, J., Charnas, R. L., Bradley, S. M. and Knowles, J. R. (1981), "Inactivation of the RTEM β -Lactamase from *Escherichia coli*", *Biochemistry* 20, 2726-2731.
- Folk, J. E. and Schirmer, E. W. (1963), "The Porcine Pancreatic Carboxypeptidase A System", *J. Biol. Chem.* 238, 3884-3894.
- Frere, J. M. (1995) *Mol. Microbiol.* 16 (3) " β -Lactamases and Bacterial Resistance to Antibiotics", 385-395.
- Ghuysen, J. -M. (1988) "Evolution of DD-Peptidases and β -Lactamases", in *Antibiotic Inhibition of Bacterial Cell surface Assembly and Function* (Actor, P., Daneo-Moore, L., Higgins, M. L., Salton, M. R. J. and Shockman, G. D., Ed.) pp. 268-284, American Society for Micro biology, Washington, D. C.
- Gold, L., Polisky, B., Uhlenbeck, O. and Yarus, M., (1995), Diversity of Oligonucleotide Functions", *Annu. Rev Biochem* 64, 763-797
- Hanahan, D. (1983), "Studies of Transformation of *Escherichia coli* with Plasmids", *J. Mol. Biol.* 166, 557-580.
- Hicke, B. J. and Stephens, A. W. (2000), "Escort Aptamers", *J. Clin. Invest.* 106, 923-928.
- Hilliard, N. P., (1995), Structure-Function Relationships in the Metallo- β -Lactamase of *Bacillus cereus* 5/B/6", Ph.D. thesis, Texas Tech University
- Hilliard, N. P. and Shaw, R. W. (1992), "Reconstitution of *Bacillus cereus* 5/B/6 Metallo- β -Lactamase Activity with Copper", *The FASEB J.* 6, p. A1008.
- Hussain, M., Pastor, F. I. J. and Lampen, J. O. (1987), "Cloning and Sequencing of the *blaZ* Gene Encoding β -Lactamase III, a Lipoprotein of *Bacillus cereus* 569/H", *J. Bacteriol.* 169, 579-586.
- Jaeger, J. A., Turner, D. H. and Zuker, M. (1989), "Improved Predictions of Secondary Structures for RNA", *Proc Natl. Acad. Sci. USA* 86, 7706-7710.
- Jaeger, J. A., Turner, D. H. and Zuker, M. (1990), "Predicting Optimal and Suboptimal Secondary Structure for RNA", *In Methods in Enzymology* 183, 281-306.

- Jellinek, D., Green, L. S., Bell, C. and Janjic, N. (1994), "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor", *Biochemistry* 33, 10450-10456.
- Joris, B., Ledent, P., Dideberg, O., Fonze, E., Lamotte-Brasseur, J., Kelly, J. A., Ghuysen, J. -M. and Frere, J. -M. (1991), "Comparison of the Sequences of Class A Beta-Lactamases and of the Secondary Structure Elements of Penicillin-Recognizing Proteins", *Antimicrob. Agents Chemother.* 35, 2294-2301.
- Joyce, G. F. (1989), "Amplification, Mutation and Selection of Catalytic RNA", *Gene* 82, 83-87.
- Kelly, J. A., Knox, J. R., Moews, P. C., Moring, J. and Zhao, H. C. (1988), "Molecular Graphics: Studying β -Lactam Inhibition in Three Dimensions", in *Antibiotic Inhibition of Bacterial Cell surface Assembly and Function* (Actor, P., Daneo-Moore, L., Higgins, M. L., Salton, M. R. J. and Shockman, G. D., Ed.) pp. 261-267, American Society for Micro biology, Washington, D. C.
- Kogut, M., Pollock, M. R. and Tridgell, E. J. (1956), "Purification of Penicillin-Induced Penicillinase of *Bacillus cereus* NRRL 569", *Biochem J.* 62, 391-401.
- Kuwabara, S., Adams, E. P. and Abraham, E. P. (1970), "Composition of β -lactamase I and β -Lactamase II from *Bacillus cereus* 569/H", *Biochem J.* 118, 475-480.
- Kuwabara, S. and Lloyd, P. H. (1971), "Protein and Carbohydrate Moieties of a Preparation of β -Lactamase II", *Biochem J.* 124, 215-220.
- Ledent, P., Raquet, X., Joris, B., Van Beeumen, J. and Frere, J. -M. (1993), "A Comparative Study of Class D Beta-Lactamases", *Biochem. J.* 292, 555-562.
- Lim, H. M., Pene, J. J. and Shaw, R. W. (1988), "Cloning, Nucleotide Sequence and Expression of the *Bacillus cereus* 5/B/6 β -Lactamase II Structural Gene" *J. Bacteriol.* 170, 2873-2878.
- Livermore, D. M. (1991), "Mechanisms of Resistance to β -Lactam Antibiotics", *Scand. J. Infect. Dis., Suppl.* 78, 7-16

- Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951), "Protein Measurement with the Folin Phenol Reagent", *J. Biol. Chem* 193, 265-275.
- Macaya, R. F., Waldron, J. A., Beutel, B. A., Gao, H., Joeston, M. E., Yang, M., Patel, R., Bertelsen, A. H. and Cook, A. G. (1995), "Structural and Functional Characterization of Potent Antithrombotic Oligonucleotides Possessing Both Quadruplex and Duplex Motifs", *Biochemistry* 34, 4478-4492.
- Matagne, A., Ledent, P., Monnaie, D., Felici, A., Jamin, M., Raquet, X., Galleni, M., Klein, D., Francois, I. and Frere, J. M. (1995), "Kinetic Study of Interaction Between BRL 42715, β -Lactamases and D-Alanyl-D-Alanyl Peptidases", *Antimicrob. Agents Chemother* 39, 227-231.
- Maugh, T. M. (1981), "A New Wave of Antibiotics Builds", *Science* 214, 1225-1228.
- Maxam, A. M. and Gilbert, W. (1977), "A New Method for Sequencing DNA", *Proc. Natl. Acad. Sci. USA* 74, 560-564.
- Meyers, J. L. and Shaw, R. W. (1989), "Production, Purification and Spectral Properties of Metal-Dependent β -Lactamases of *Bacillus cereus*", *Biochem. Biophys. Acta* 995, 264-272.
- Mollard, C., Moali, C., Papamichael, C., Damblon, C., Vessilier, S., Amicosante, G., Schofield, C. J., Galleni, M., Frere, J. M. and Roberts, G. C. (2001), "Thiomandelic Acid, a Broad Spectrum Inhibitor of Zinc β -Lactamases", *J. Biol. Chem* 276 45015-45023.
- Nagai, K. and Thogersen, H. C. (1984), "Generation of β -Globin by Sequence-Specific Proteolysis of a Hybrid Protein Produced in *Escherichia coli*", *Nature* 309, 810-812.
- Neu, H. C. (1992), "The Crisis in Antibiotic Resistance", *Science* 257, 1064-1073.
- Payne, D. J. (1993), "Metallo- β -lactamases-A New Therapeutic Challenge", *J. Med. Microbiol.* 39, 993-999.

- Payne, D. J., Bateson, J. H., Gasson, B. C., Proctor, D., Khushi, T., Farmer, T. H., Tolson, D. A., Bell, D., Skett, P. W., Marshall, A. C., Reid, R., Ghosez, L., Combret, Y. and Marchand-Brynaert, J. (1997), "Inhibition of Metallo- β -Lactamases by a Series of Mercaptoacetic Acid Thiol Ester Derivatives", *Antimicrob. Agents Chemother.* 41, 135-140.
- Pitout, J. D. D., Sanders, C. C. and Sanders, W. E. (1997), "Antimicrobial Resistance with Focus on β -Lactam Resistance in Gram-negative Bacilli", *Am J. Med.* 103, 51-59.
- Rahil, J. and Pratt, R. F. (1991), "Phosphonate Monoester Inhibitors of Class A β -Lactamases", *Biochem J.* 275, 793-795.
- Rasmussen, B. A., Yang, Y., Jacobs, N. and Bush, K. (1994), "Contribution of Enzymatic Properties, Cell Permeability and Enzyme Expression to Microbial Activities of Beta-lactams in Three *Bacteroides fragilis* Isolates that Harbor a Metallo- β -Lactamase gene", *Antimicrob. Agents Chemother.* 38, 2116-2120.
- Reddy, P., Peterkofsky, A. and McKenney, K. (1989), "Hyperexpression and Purification of Escherichia coli Adenylate Cyclase Using a Vector Designed for Expression of Lethal Gene Products", *Nucleic Acids Res.* 17, 10473-10488.
- Robertson, D. L. and Joyce, G. F. (1990), "Selection *in vitro* of an RNA Enzyme that Specifically Cleaves Single-Stranded DNA", *Nature* 344, 467-468.
- Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L. and Janjic, N. (1998), "2'-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF₁₆₅), *Journal of Biological Chemistry* 273, 20556-20567.
- Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989), "Electrophoretic Purification of Oligonucleotides", *Molecular Cloning: a laboratory manual*, 2ed, pp. 7.70, and 7.76, Cold Spring Harbor Laboratory Press, New York.
- Sabath, L. D. and Abarham, E. P. (1966), "Zinc as a Cofactor for Cephalosporinase from *Bacillus cereus* 569", *Biochem J.* 98, 11c-13c.

- Scrofani, S. D., Chung, J., Huntley, J. J., Benkovic, S. J., Wright, P. E. and Dyson, H. J. (1999), "NMR Characterization of the Metallo- β -Lactamase from *Bacteroides fragilis* and Its Interaction with a Tight-Binding Inhibitor", 44, 14507-14514.
- Shaw, R. W., Clark, S. D., Hilliard, N. P. and Harman, J. G. (1991), "Hyperexpression in *Escherichia coli*, Purification and Characterization of the Metallo- β -lactamase of *Bacillus cereus* 5/B/6", *Prot. Exp. Purif.* 2, 151-157.
- Suskoviae, B., Vajtner, Z. and Naumski, R. (1991), "Synthesis and Biological Activities of Some Peptidoglycan Monomer Derivatives", *Tetrahedron* 47, 8407-8416.
- Sutton, B. J., Artymiuk, P. J., Cordero-Borboa, A. E., Little, C., Philips, D. C. and Waley, S. G. (1987), "X-Ray Crystallographic Study of β -Lactamase II from *Bacillus cereus* at 0.35 nm Resolution", *Biochem J.* 248, 181-188.
- Tasset, D. M., Kubik, M. F. and Steiner, W. (1997), "Oligonucleotide Inhibitors of Human Thrombin that Bind Distinct Epitopes", *J. Mol. Biol.* 272, 688-698.
- Thatcher, D. R. (1975), "Partial Amino Acid Sequence of the Extracellular β -Lactamase I of *Bacillus cereus* 569/H", *Biochem J.* 147, 313-326.
- Tsiang, M., Gibbs, C. S., Griffin, L. C., Dunn, K. E. and Leung, L. K. (1995), "Selection of a Suppressor mutation That Restores Affinity of an Oligonucleotide Inhibitor for Thrombin Using *in Vitro* Genetics", *J. Biol. Chem.* 270, 19370-19376.
- Tuerk, C. and Gold, L. (1990), "Systematic Evolution of Ligands by Exponential Enrichment", *Science* 249, 505-510.
- Turner, D. H., Sugimoto, N. and Freier, S. M. (1988), "RNA Structure Prediction", *Annu. Rev. Biophys. Biophys. Chem.* 17, 167-192.
- Willis, M. C., Collins, B. D., Zhang, T., Green, L. S., Sebesta, D. P., Bell, C., Kellogg, E., Gill, S. C., Magallanez, A., Knauer, S., Bendele, R. A., Gill, P. S., Janjic, N. and Collins, B. (1998), "Liposome-Anchored Vascular Endothelial Growth Factor Aptamers", *Bioconjug Chem* 9, 573-582.

- Yang, K. W. and Crowder, M. W. (1999), "Inhibition Studies on the Metallo- β -lactamase from *Stenotrophomonas maltophilia*", *Arch. Biochem. Biophys.* 368, 1-6.
- Zuber, M., Patterson, T. A. and Court, D. L. (1987), "Analysis of *nutR*, a Site Required for Transcriptional Antitermination in Phage λ ", *Proc. Natl. Acad. Sci. USA* 84, 4514-4518.
- Zuker, M. (1989), "On Finding All Suboptimal Foldings of an RNA Molecule" *Science* 244, 48-52.

1/41






FIGURE 1

2/41




Penicillins




Cephalosporins

FIGURE 2

3/41



Penicillins



D-alanyl-D-alanine-peptidoglycan

FIGURE 3

4/41




FIGURE 4

5/41




FIGURE 5

6/41




FIGURE 6

7/41




FIGURE 7

8/41




FIGURE 8

9/41




FIGURE 9

10/41




FIGURE 10

11/41




FIGURE 11

12/41




FIGURE 12

13/41




FIGURE 13

14/41




FIGURE 14

15/41



FIGURE 15

16/41




FIGURE 16

17/41




FIGURE 17

18/41




FIGURE 18

19/41




Figure 19

20/41




FIGURE 20

21/41





FIGURE 21

22/41**FIGURE 22**

23/41




FIGURE 23

24/41




FIGURE 24

25/41




FIGURE 25

26/41




FIGURE 26

27/41




FIGURE 27

28/41




FIGURE 28

29/41

A C
A T
A•T
C•G
5'A A C•G A T C G G T G C A C A T G T C G A A 3'

FIGURE 29

30/41




FIGURE 30

31/41




FIGURE 31

32/41



FIGURE 32

33/41




FIGURE 33

34/41




FIGURE 34

35/41




FIGURE 35

36/41





FIGURE 36

37/41**FIGURE 37**

38/41




FIGURE 38

39/41




FIGURE 39

40/41




FIGURE 40

41/41




FIGURE 41

SEQUENCE LISTING

<110> Texas Tech University
Shaw, Robert W.

<120> Inhibition of metallo-beta-lactamase

<130> 218601.00003

<160> 6

<170> PatentIn version 3.1

<210> 1

<211> 16

<212> DNA

<213> artificial sequence

<220>

<223> A 16 mer with a NdeI restriction site for SELEX.

<400> 1

gcgccatatg cgcgcg

16

<210> 2

<211> 15

<212> DNA

<213> artificial sequence

<220>

<223> A 15 mer with a SecI restriction site for SELEX.

<400> 2

cgcgagctcc gcgcg

15

<210> 3

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> This is the aptamer sequence after 16 rounds of SELEX.

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is A or T or G or C

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is A or T or G or C

<220>

<221> misc_feature

<222> (6)..(8)

<223> N is A or T or G or C

<220>

<221> misc_feature

<222> (11)..(13)

<223> N is A or T or G or C

<220>

<221> misc_feature

<222> (15)..(15)

<223> N is A or T or G or C

<220>

<221> misc_feature

<222> (17)..(18)

<223> N is A or T or G or C

<220>

<221> misc_feature

<222> (20)..(21)

<223> N is A or T or G or C

<220>

<221> misc_feature

<222> (25)..(28)

<223> N is A or T or G or C

<400> 3

ancnannntt nntngnngn ncatnnnnaa

30

<210> 4

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> This is the aptamer 30-mer sequence after 21 rounds of SELEX.

<400> 4

aaccaaactt ggatcggtgc acatgtcgaa

30

<210> 5

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> This is a 10 mer that contains a specific stem loop structure

<220>

<221> stem_loop

<222> (1)..(10)

<223>

<400> 5
ccaaacttgg

10

<210> 6
<211> 61
<212> DNA
<213> artificial sequence

<220>
<223> the aptamer (61-mer)

<400> 6
gcgccatatg cgcgcgaacc aaacttggat cggatgcacat gtcgaacgcg cggagctcgc 60
g 61

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.